https://trial.medpath.com/news/astria-therapeutics-announces-fda-clearance-of-ind-application-for-star-0310-a-biospace 2024-12-10T19:41:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astria-therapeutics-announces-fda-clearance-of-ind-application-for-star-0310-a-biospace 2024-12-10T19:41:48+00:00 weekly 0.7 https://trial.medpath.com/news/revolutionary-cancer-drug-could-remove-side-effects-from-radiation-treatments-study-finds 2024-12-10T19:40:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/revolutionary-cancer-drug-could-remove-side-effects-from-radiation-treatments-study-finds 2024-12-10T19:40:38+00:00 weekly 0.7 https://trial.medpath.com/news/lisata-therapeutics-announces-completion-of-enrollment-in-the-cendifox-trial 2024-12-10T19:39:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lisata-therapeutics-announces-completion-of-enrollment-in-the-cendifox-trial 2024-12-10T19:39:48+00:00 weekly 0.7 https://trial.medpath.com/news/harnessing-ai-for-smarter-health-policy-research-school-of-public-health-brown-university 2024-12-10T19:19:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/harnessing-ai-for-smarter-health-policy-research-school-of-public-health-brown-university 2024-12-10T19:19:49+00:00 weekly 0.7 https://trial.medpath.com/news/cervomed-announces-topline-data-from-rewind-lb-phase-2b-clinical-trial-in-patients-with 2024-12-10T19:12:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cervomed-announces-topline-data-from-rewind-lb-phase-2b-clinical-trial-in-patients-with 2024-12-10T19:12:07+00:00 weekly 0.7 https://trial.medpath.com/news/ash-2024-regeneron-s-ordspono-faces-challenges-but-positive-results-signal-hope 2024-12-10T19:11:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ash-2024-regeneron-s-ordspono-faces-challenges-but-positive-results-signal-hope 2024-12-10T19:11:41+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-to-test-obesity-medications-as-treatments-for-alcohol-and-drug-addiction-stat-news 2024-12-10T19:05:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-to-test-obesity-medications-as-treatments-for-alcohol-and-drug-addiction-stat-news 2024-12-10T19:05:14+00:00 weekly 0.7 https://trial.medpath.com/news/alveron-pharma-closes-eur5-million-seed-extension-financing-to-accelerate-breakthrough-ich-therapy 2024-12-10T18:50:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alveron-pharma-closes-eur5-million-seed-extension-financing-to-accelerate-breakthrough-ich-therapy 2024-12-10T18:50:41+00:00 weekly 0.7 https://trial.medpath.com/news/geron-announces-new-imerge-analyses-presented-at-ash-suggesting-clinical-activity-of 2024-12-10T18:41:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/geron-announces-new-imerge-analyses-presented-at-ash-suggesting-clinical-activity-of 2024-12-10T18:41:35+00:00 weekly 0.7 https://trial.medpath.com/news/arvinas-pfizer-partner-cancer-drug-trial-shows-63-clinical-benefit-in-breast-cancer-patients 2024-12-10T18:31:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arvinas-pfizer-partner-cancer-drug-trial-shows-63-clinical-benefit-in-breast-cancer-patients 2024-12-10T18:31:47+00:00 weekly 0.7 https://trial.medpath.com/news/btk-degrader-bgb-16673-shows-promise-in-r-r-wm-and-cll-sll-cancer-network 2024-12-10T18:28:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/btk-degrader-bgb-16673-shows-promise-in-r-r-wm-and-cll-sll-cancer-network 2024-12-10T18:28:23+00:00 weekly 0.7 https://trial.medpath.com/news/new-strategy-for-vivoryon-as-second-failed-alzheimer-s-trial-shows-kidney-promise 2024-12-10T18:15:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-strategy-for-vivoryon-as-second-failed-alzheimer-s-trial-shows-kidney-promise 2024-12-10T18:15:47+00:00 weekly 0.7 https://trial.medpath.com/news/carvykti-significantly-boosts-survival-mrd-negativity-in-relapsed-multiple-myeloma 2024-12-10T17:26:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/carvykti-significantly-boosts-survival-mrd-negativity-in-relapsed-multiple-myeloma 2024-12-10T17:26:52+00:00 weekly 0.7 https://trial.medpath.com/news/merus-mrus-fda-approval-and-speculative-future-in-cancer-therapy-yahoo-finance 2024-12-10T17:13:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merus-mrus-fda-approval-and-speculative-future-in-cancer-therapy-yahoo-finance 2024-12-10T17:13:40+00:00 weekly 0.7 https://trial.medpath.com/news/ramose-phase-ii-trial-finds-promising-results-for-osimertinib-and-ramucirumab-in-non-small 2024-12-10T16:14:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ramose-phase-ii-trial-finds-promising-results-for-osimertinib-and-ramucirumab-in-non-small 2024-12-10T16:14:47+00:00 weekly 0.7 https://trial.medpath.com/news/humanetics-secures-additional-funding-to-advance-development-of-its-drug-to-prevent 2024-12-10T15:55:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/humanetics-secures-additional-funding-to-advance-development-of-its-drug-to-prevent 2024-12-10T15:55:19+00:00 weekly 0.7 https://trial.medpath.com/news/pafolacianine-shows-no-serious-adverse-effects-in-lung-cancer-surgery 2024-12-10T15:26:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pafolacianine-shows-no-serious-adverse-effects-in-lung-cancer-surgery 2024-12-10T15:26:04+00:00 weekly 0.7 https://trial.medpath.com/news/uk-clinical-trials-performance-improves-but-remains-in-intensive-care 2024-12-10T15:09:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uk-clinical-trials-performance-improves-but-remains-in-intensive-care 2024-12-10T15:09:49+00:00 weekly 0.7 https://trial.medpath.com/news/why-is-cancer-focused-chimerix-stock-trading-higher-on-tuesday-yahoo-finance 2024-12-10T14:50:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/why-is-cancer-focused-chimerix-stock-trading-higher-on-tuesday-yahoo-finance 2024-12-10T14:50:08+00:00 weekly 0.7 https://trial.medpath.com/news/the-start-center-for-cancer-research-expands-its-capabilities-to-support-early-phase 2024-12-10T14:44:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-start-center-for-cancer-research-expands-its-capabilities-to-support-early-phase 2024-12-10T14:44:29+00:00 weekly 0.7 https://trial.medpath.com/news/genmab-delivers-promising-data-from-cancer-drug-in-two-new-clinical-trials-medwatch 2024-12-10T14:25:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genmab-delivers-promising-data-from-cancer-drug-in-two-new-clinical-trials-medwatch 2024-12-10T14:25:38+00:00 weekly 0.7 https://trial.medpath.com/news/uniqure-gets-fda-ok-to-seek-accelerated-approval-stat-news 2024-12-10T14:20:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uniqure-gets-fda-ok-to-seek-accelerated-approval-stat-news 2024-12-10T14:20:00+00:00 weekly 0.7 https://trial.medpath.com/news/atossa-therapeutics-to-present-pharmacokinetic-and-globenewswire 2024-12-10T14:10:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/atossa-therapeutics-to-present-pharmacokinetic-and-globenewswire 2024-12-10T14:10:43+00:00 weekly 0.7 https://trial.medpath.com/news/theradaptive-obtains-fda-ide-approval-to-study-osteoadapttm-sp-in-additional-spinal 2024-12-10T14:04:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/theradaptive-obtains-fda-ide-approval-to-study-osteoadapttm-sp-in-additional-spinal 2024-12-10T14:04:16+00:00 weekly 0.7 https://trial.medpath.com/news/thiogenesis-announces-presentation-on-umdf-webcast-featuring-clinical-trials-in 2024-12-10T14:03:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/thiogenesis-announces-presentation-on-umdf-webcast-featuring-clinical-trials-in 2024-12-10T14:03:56+00:00 weekly 0.7 https://trial.medpath.com/news/curis-reports-promising-aml-study-results-by-investing-com 2024-12-10T13:46:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/curis-reports-promising-aml-study-results-by-investing-com 2024-12-10T13:46:13+00:00 weekly 0.7 https://trial.medpath.com/news/sirus-therapeutics-announces-positive-signals-from-phase-i-sirna-trial 2024-12-10T13:43:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sirus-therapeutics-announces-positive-signals-from-phase-i-sirna-trial 2024-12-10T13:43:46+00:00 weekly 0.7 https://trial.medpath.com/news/heart-specialists-praise-health-canada-approval-of-weight-loss-drug-wegovy-cp24 2024-12-10T13:41:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/heart-specialists-praise-health-canada-approval-of-weight-loss-drug-wegovy-cp24 2024-12-10T13:41:18+00:00 weekly 0.7 https://trial.medpath.com/news/sellas-life-sciences-triggers-interim-analysis-in-phase-3-regal-trial-of-gps-in-acute 2024-12-10T13:39:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sellas-life-sciences-triggers-interim-analysis-in-phase-3-regal-trial-of-gps-in-acute 2024-12-10T13:39:09+00:00 weekly 0.7 https://trial.medpath.com/news/fda-opens-accelerated-approval-path-for-clene-s-breakthrough-als-treatment-after-78 2024-12-10T13:32:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-opens-accelerated-approval-path-for-clene-s-breakthrough-als-treatment-after-78 2024-12-10T13:32:28+00:00 weekly 0.7 https://trial.medpath.com/news/curocell-s-car-t-therapy-picked-as-2nd-drug-for-expediated-approval-and-market-launch 2024-12-10T13:24:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/curocell-s-car-t-therapy-picked-as-2nd-drug-for-expediated-approval-and-market-launch 2024-12-10T13:24:10+00:00 weekly 0.7 https://trial.medpath.com/news/global-biosimilars-market-set-to-triple-to-114-billion-by-2031-driven-by-patent-expirations-and-cost-advantages 2024-12-10T13:23:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-biosimilars-market-set-to-triple-to-114-billion-by-2031-driven-by-patent-expirations-and-cost-advantages 2024-12-10T13:23:20+00:00 weekly 0.7 https://trial.medpath.com/news/sutro-biopharma-announces-selected-dose-for-luvelta-and-globenewswire 2024-12-10T13:11:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sutro-biopharma-announces-selected-dose-for-luvelta-and-globenewswire 2024-12-10T13:11:34+00:00 weekly 0.7 https://trial.medpath.com/news/renovorx-ceo-to-host-investor-fireside-chat-on-tuesday-december-17th-at-4-30-p-m-et 2024-12-10T13:10:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/renovorx-ceo-to-host-investor-fireside-chat-on-tuesday-december-17th-at-4-30-p-m-et 2024-12-10T13:10:13+00:00 weekly 0.7 https://trial.medpath.com/news/onkure-announces-encouraging-preliminary-safety-and-pharmacokinetic-data-from-pikture-01-trial-of-oki-219 2024-12-10T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/onkure-announces-encouraging-preliminary-safety-and-pharmacokinetic-data-from-pikture-01-trial-of-oki-219 2024-12-10T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/quantum-biopharma-progresses-with-drug-trial-dosing-investing-com 2024-12-10T12:46:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/quantum-biopharma-progresses-with-drug-trial-dosing-investing-com 2024-12-10T12:46:43+00:00 weekly 0.7 https://trial.medpath.com/news/lyell-immunopharma-announces-promising-initial-clinical-data-for-impt-314-in-treatment 2024-12-10T12:32:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lyell-immunopharma-announces-promising-initial-clinical-data-for-impt-314-in-treatment 2024-12-10T12:32:44+00:00 weekly 0.7 https://trial.medpath.com/news/uniqure-announces-alignment-with-fda-on-key-elements-of-accelerated-approval-pathway 2024-12-10T12:13:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uniqure-announces-alignment-with-fda-on-key-elements-of-accelerated-approval-pathway 2024-12-10T12:13:30+00:00 weekly 0.7 https://trial.medpath.com/news/scilex-forms-major-joint-venture-to-develop-novel-obesity-alzheimer-s-drug-after 2024-12-10T12:06:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scilex-forms-major-joint-venture-to-develop-novel-obesity-alzheimer-s-drug-after 2024-12-10T12:06:36+00:00 weekly 0.7 https://trial.medpath.com/news/merakris-therapeutics-announces-open-enrollment-for-phase-ii-clinical-trial-of-financial-post 2024-12-10T11:34:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merakris-therapeutics-announces-open-enrollment-for-phase-ii-clinical-trial-of-financial-post 2024-12-10T11:34:24+00:00 weekly 0.7 https://trial.medpath.com/news/glp-1-meds-may-lower-clot-risk-in-people-with-diabetes 2024-12-10T11:05:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glp-1-meds-may-lower-clot-risk-in-people-with-diabetes 2024-12-10T11:05:45+00:00 weekly 0.7 https://trial.medpath.com/news/iaso-bio-s-car-t-therapy-shows-sustained-efficacy-in-multiple-myeloma-patients-with-renal-impairment 2024-12-10T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iaso-bio-s-car-t-therapy-shows-sustained-efficacy-in-multiple-myeloma-patients-with-renal-impairment 2024-12-10T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/hvivo-plc-aim-hvo-ps11-5m-rsv-contract-and-notice-of-trading-update-share-talk 2024-12-10T09:04:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hvivo-plc-aim-hvo-ps11-5m-rsv-contract-and-notice-of-trading-update-share-talk 2024-12-10T09:04:22+00:00 weekly 0.7 https://trial.medpath.com/news/olverembatinib-shows-promise-as-second-line-therapy-for-non-t315i-mutant-cp-cml 2024-12-10T08:31:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/olverembatinib-shows-promise-as-second-line-therapy-for-non-t315i-mutant-cp-cml 2024-12-10T08:31:00+00:00 weekly 0.7 https://trial.medpath.com/news/ixico-lands-ps500k-phase-ii-huntington-s-contract-aim-ixi-otc-phyof-proactive-investors 2024-12-10T08:12:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ixico-lands-ps500k-phase-ii-huntington-s-contract-aim-ixi-otc-phyof-proactive-investors 2024-12-10T08:12:20+00:00 weekly 0.7 https://trial.medpath.com/news/santhera-receives-positive-recommendation-from-nice-for-agamree-r-vamorolone-as 2024-12-10T06:11:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/santhera-receives-positive-recommendation-from-nice-for-agamree-r-vamorolone-as 2024-12-10T06:11:28+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-s-tavapadon-shows-promise-in-phase-3-parkinson-s-disease-trial 2024-12-10T06:06:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-s-tavapadon-shows-promise-in-phase-3-parkinson-s-disease-trial 2024-12-10T06:06:25+00:00 weekly 0.7 https://trial.medpath.com/news/new-and-updated-data-for-roche-s-fixed-duration-columvi-and-globenewswire 2024-12-10T06:02:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-and-updated-data-for-roche-s-fixed-duration-columvi-and-globenewswire 2024-12-10T06:02:08+00:00 weekly 0.7 https://trial.medpath.com/news/experts-challenge-os-as-gold-standard-endpoint-in-cancer-drug-trials-pfs-gains-clinical-relevance 2024-12-10T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/experts-challenge-os-as-gold-standard-endpoint-in-cancer-drug-trials-pfs-gains-clinical-relevance 2024-12-10T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/comprehensive-management-guidelines-released-for-talquetamab-treatment-in-multiple-myeloma-patients 2024-12-10T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/comprehensive-management-guidelines-released-for-talquetamab-treatment-in-multiple-myeloma-patients 2024-12-10T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eye-disease-focused-kodiak-sciences-is-a-promising-turnaround-story-for-2025-benzinga 2024-12-10T05:36:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eye-disease-focused-kodiak-sciences-is-a-promising-turnaround-story-for-2025-benzinga 2024-12-10T05:36:22+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approved-vowst-offers-novel-treatment-approach-for-recurrent-c-difficile-infections 2024-12-10T05:05:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approved-vowst-offers-novel-treatment-approach-for-recurrent-c-difficile-infections 2024-12-10T05:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/immune-onc-therapeutics-presents-updated-data-from-phase-1b-study-of-io-202-biospace 2024-12-10T05:02:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immune-onc-therapeutics-presents-updated-data-from-phase-1b-study-of-io-202-biospace 2024-12-10T05:02:14+00:00 weekly 0.7 https://trial.medpath.com/news/lyell-presents-positive-initial-clinical-data-from-the-phase-1-2-clinical-trial-of-impt-314-for 2024-12-10T05:02:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lyell-presents-positive-initial-clinical-data-from-the-phase-1-2-clinical-trial-of-impt-314-for 2024-12-10T05:02:14+00:00 weekly 0.7 https://trial.medpath.com/news/glenmark-s-blood-cancer-drug-isb-2001-shows-83-response-rate-in-phase-1-multiple-myeloma-trial 2024-12-10T04:29:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glenmark-s-blood-cancer-drug-isb-2001-shows-83-response-rate-in-phase-1-multiple-myeloma-trial 2024-12-10T04:29:37+00:00 weekly 0.7 https://trial.medpath.com/news/immutep-initiates-phase-iii-trial-for-lung-cancer-markets-insider 2024-12-10T03:49:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immutep-initiates-phase-iii-trial-for-lung-cancer-markets-insider 2024-12-10T03:49:41+00:00 weekly 0.7 https://trial.medpath.com/news/pediatric-cancer-clinical-trial-research-should-include-social-determinants-of-health 2024-12-10T02:50:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pediatric-cancer-clinical-trial-research-should-include-social-determinants-of-health 2024-12-10T02:50:02+00:00 weekly 0.7 https://trial.medpath.com/news/ghana-becomes-first-river-blindness-endemic-country-to-approve-moxidectin-biomelbourne-network 2024-12-10T02:39:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ghana-becomes-first-river-blindness-endemic-country-to-approve-moxidectin-biomelbourne-network 2024-12-10T02:39:40+00:00 weekly 0.7 https://trial.medpath.com/news/zealand-pharma-announces-first-participant-enrolled-in-phase-2b-zupreme-1-trial-of-petrelintide-in-people-with-overweight-or-obesity 2024-12-10T02:12:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zealand-pharma-announces-first-participant-enrolled-in-phase-2b-zupreme-1-trial-of-petrelintide-in-people-with-overweight-or-obesity 2024-12-10T02:12:56+00:00 weekly 0.7 https://trial.medpath.com/news/beigene-s-brukinsa-shows-breakthrough-71-risk-reduction-in-5-year-cll-study-at-ash 2024-12-10T01:31:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/beigene-s-brukinsa-shows-breakthrough-71-risk-reduction-in-5-year-cll-study-at-ash 2024-12-10T01:31:17+00:00 weekly 0.7 https://trial.medpath.com/news/comprehensive-treatment-options-expand-for-non-familial-hypercholesterolemia-management 2024-12-10T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/comprehensive-treatment-options-expand-for-non-familial-hypercholesterolemia-management 2024-12-10T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-white-paper-highlights-critical-success-factors-for-modern-pharmaceutical-product-launches 2024-12-10T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-white-paper-highlights-critical-success-factors-for-modern-pharmaceutical-product-launches 2024-12-10T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/kites-yescarta-only-car-t-cell-therapy-to-show-durable-response-and-long-gilead-sciences 2024-12-10T00:34:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kites-yescarta-only-car-t-cell-therapy-to-show-durable-response-and-long-gilead-sciences 2024-12-10T00:34:16+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-gene-therapy-offers-new-hope-to-child-with-muscular-dystrophy-the-tennessean 2024-12-10T00:18:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-gene-therapy-offers-new-hope-to-child-with-muscular-dystrophy-the-tennessean 2024-12-10T00:18:40+00:00 weekly 0.7 https://trial.medpath.com/news/positive-phase-3-trial-results-for-rilzabrutinib-support-buy-rating 2024-12-10T00:07:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/positive-phase-3-trial-results-for-rilzabrutinib-support-buy-rating 2024-12-10T00:07:00+00:00 weekly 0.7 https://trial.medpath.com/news/tempus-announces-four-abstracts-accepted-for-presentation-at-the-2024-san-antonio-breast-cancer-symposium 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tempus-announces-four-abstracts-accepted-for-presentation-at-the-2024-san-antonio-breast-cancer-symposium 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/major-milestone-for-uq-spin-out-s-promising-mnd-drug 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/major-milestone-for-uq-spin-out-s-promising-mnd-drug 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/with-promising-early-data-in-triple-negative-breast-cancer-a-new-bispecific-heats-up 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/with-promising-early-data-in-triple-negative-breast-cancer-a-new-bispecific-heats-up 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/correcting-and-replacing-maat-pharma-presented-positive-updated-data-on-maat013-in-the-early-access-program-at-ash-2024-annual-meeting 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/correcting-and-replacing-maat-pharma-presented-positive-updated-data-on-maat013-in-the-early-access-program-at-ash-2024-annual-meeting 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/year-in-review-chronic-lymphocytic-leukemia 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/year-in-review-chronic-lymphocytic-leukemia 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/syntara-announces-positive-interim-data-in-phase-2-study-of-snt-5505-in-myelofibrosis 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/syntara-announces-positive-interim-data-in-phase-2-study-of-snt-5505-in-myelofibrosis 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/tourmaline-bio-highlights-cardiovascular-inflammation-focus-and-announces-key-clinical-and-strategic-updates-at-investor-day 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tourmaline-bio-highlights-cardiovascular-inflammation-focus-and-announces-key-clinical-and-strategic-updates-at-investor-day 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/what-s-going-on-with-recursion-pharmaceuticals-stock 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/what-s-going-on-with-recursion-pharmaceuticals-stock 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-secures-950k-private-placement-to-advance-thio-clinical-trials 2024-12-09T23:06:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maia-biotechnology-secures-950k-private-placement-to-advance-thio-clinical-trials 2024-12-09T23:06:41+00:00 weekly 0.7 https://trial.medpath.com/news/regeneron-s-odronextamab-shows-remarkable-100-response-rate-in-lymphoma 2024-12-09T22:56:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regeneron-s-odronextamab-shows-remarkable-100-response-rate-in-lymphoma 2024-12-09T22:56:01+00:00 weekly 0.7 https://trial.medpath.com/news/longest-follow-up-data-reported-for-kites-tecartus-car-t-cell-therapy-at-ash-2024 2024-12-09T22:47:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/longest-follow-up-data-reported-for-kites-tecartus-car-t-cell-therapy-at-ash-2024 2024-12-09T22:47:26+00:00 weekly 0.7 https://trial.medpath.com/news/ash-2024-astrazeneca-set-to-take-a-bite-out-of-follicular-lymphoma-market 2024-12-09T22:40:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ash-2024-astrazeneca-set-to-take-a-bite-out-of-follicular-lymphoma-market 2024-12-09T22:40:19+00:00 weekly 0.7 https://trial.medpath.com/news/spotlight-glow-trials-lead-to-fda-approval-of-zolbetuximab-clzb-with-chemotherapy 2024-12-09T22:15:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spotlight-glow-trials-lead-to-fda-approval-of-zolbetuximab-clzb-with-chemotherapy 2024-12-09T22:15:51+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-rezdiffra-first-fatty-liver-disease-drug-explained-woman-s-world 2024-12-09T21:49:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-rezdiffra-first-fatty-liver-disease-drug-explained-woman-s-world 2024-12-09T21:49:37+00:00 weekly 0.7 https://trial.medpath.com/news/sellas-stock-announces-positive-data-from-phase-2-trial-of-sls009-rttnews 2024-12-09T21:36:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sellas-stock-announces-positive-data-from-phase-2-trial-of-sls009-rttnews 2024-12-09T21:36:35+00:00 weekly 0.7 https://trial.medpath.com/news/theratechnologies-initial-efficacy-data-from-ovarian-cancer-drug-trial-shows-encouraging-results 2024-12-09T21:36:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/theratechnologies-initial-efficacy-data-from-ovarian-cancer-drug-trial-shows-encouraging-results 2024-12-09T21:36:16+00:00 weekly 0.7 https://trial.medpath.com/news/krystal-biotech-provides-update-on-ema-s-ongoing-regulatory-review-of-b-vec-for 2024-12-09T21:20:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/krystal-biotech-provides-update-on-ema-s-ongoing-regulatory-review-of-b-vec-for 2024-12-09T21:20:32+00:00 weekly 0.7 https://trial.medpath.com/news/protagonist-reports-final-results-from-rusfertide-phase-2-revive-study-showing-durable 2024-12-09T21:19:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/protagonist-reports-final-results-from-rusfertide-phase-2-revive-study-showing-durable 2024-12-09T21:19:20+00:00 weekly 0.7 https://trial.medpath.com/news/relay-therapeutics-to-present-updated-clinical-data-on-rly-2608-in-hr-her2-globenewswire 2024-12-09T21:10:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/relay-therapeutics-to-present-updated-clinical-data-on-rly-2608-in-hr-her2-globenewswire 2024-12-09T21:10:47+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-acetadote-r-snda-stock-titan 2024-12-09T21:10:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-acetadote-r-snda-stock-titan 2024-12-09T21:10:12+00:00 weekly 0.7 https://trial.medpath.com/news/survey-titrating-trofinetide-improves-tolerability-among-rett-syndrome-patients 2024-12-09T20:58:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/survey-titrating-trofinetide-improves-tolerability-among-rett-syndrome-patients 2024-12-09T20:58:32+00:00 weekly 0.7 https://trial.medpath.com/news/new-drug-review-donanemab-azbt-approved-for-early-symptomatic-alzheimer-disease 2024-12-09T20:54:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-drug-review-donanemab-azbt-approved-for-early-symptomatic-alzheimer-disease 2024-12-09T20:54:29+00:00 weekly 0.7 https://trial.medpath.com/news/venetoclax-cladribine-improves-response-rates-in-aml-mds-cohorts-cancer-network 2024-12-09T20:39:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/venetoclax-cladribine-improves-response-rates-in-aml-mds-cohorts-cancer-network 2024-12-09T20:39:11+00:00 weekly 0.7 https://trial.medpath.com/news/insights-on-ucb-s-commitment-to-advancing-rare-epilepsy-care-neurologylive 2024-12-09T20:16:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/insights-on-ucb-s-commitment-to-advancing-rare-epilepsy-care-neurologylive 2024-12-09T20:16:43+00:00 weekly 0.7 https://trial.medpath.com/news/beacon-therapeutics-announces-positive-3-month-data-from-phase-2-dawn-trial-of-agtc 2024-12-09T20:10:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/beacon-therapeutics-announces-positive-3-month-data-from-phase-2-dawn-trial-of-agtc 2024-12-09T20:10:11+00:00 weekly 0.7 https://trial.medpath.com/news/secura-bio-presented-new-data-from-its-phase-2-primo-trial-of-copiktra-r-duvelisib-in 2024-12-09T20:07:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/secura-bio-presented-new-data-from-its-phase-2-primo-trial-of-copiktra-r-duvelisib-in 2024-12-09T20:07:50+00:00 weekly 0.7 https://trial.medpath.com/news/corbus-pharma-launches-phase-1-trial-for-novel-cancer-immunotherapy-crb-601 2024-12-09T19:57:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/corbus-pharma-launches-phase-1-trial-for-novel-cancer-immunotherapy-crb-601 2024-12-09T19:57:35+00:00 weekly 0.7 https://trial.medpath.com/news/affimed-reports-promising-phase-1-efficacy-and-safety-data-for-afm28-in-relapsed-refractory-acute-myeloid-leukemia 2024-12-09T19:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/affimed-reports-promising-phase-1-efficacy-and-safety-data-for-afm28-in-relapsed-refractory-acute-myeloid-leukemia 2024-12-09T19:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-enrolled-in-inspiremd-s-cguardians-ii-pivotal-study-vascular-news 2024-12-09T19:28:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-patient-enrolled-in-inspiremd-s-cguardians-ii-pivotal-study-vascular-news 2024-12-09T19:28:58+00:00 weekly 0.7 https://trial.medpath.com/news/icer-potential-new-pain-medication-offers-small-savings-managed-healthcare-executive 2024-12-09T19:13:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/icer-potential-new-pain-medication-offers-small-savings-managed-healthcare-executive 2024-12-09T19:13:08+00:00 weekly 0.7 https://trial.medpath.com/news/deferasirox-achieves-transfusion-independence-in-mds-anemia-targeted-oncology 2024-12-09T19:04:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/deferasirox-achieves-transfusion-independence-in-mds-anemia-targeted-oncology 2024-12-09T19:04:09+00:00 weekly 0.7 https://trial.medpath.com/news/carta-healthcare-to-power-oncology-research-and-clinical-trials-with-acquisition-pr-newswire 2024-12-09T19:01:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/carta-healthcare-to-power-oncology-research-and-clinical-trials-with-acquisition-pr-newswire 2024-12-09T19:01:35+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-cancer-treatments 2024-12-09T18:56:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-new-cancer-treatments 2024-12-09T18:56:44+00:00 weekly 0.7 https://trial.medpath.com/news/adding-chemoradiation-in-perioperative-gastric-cancer-treatment-improves-pathologic 2024-12-09T18:47:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adding-chemoradiation-in-perioperative-gastric-cancer-treatment-improves-pathologic 2024-12-09T18:47:57+00:00 weekly 0.7 https://trial.medpath.com/news/endo-receives-u-s-fda-approval-of-manufacturing-facility-in-indore-india 2024-12-09T18:20:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/endo-receives-u-s-fda-approval-of-manufacturing-facility-in-indore-india 2024-12-09T18:20:58+00:00 weekly 0.7 https://trial.medpath.com/news/adenosine-antagonists-clinical-trial-pipeline-analysis-10-globenewswire 2024-12-09T18:05:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adenosine-antagonists-clinical-trial-pipeline-analysis-10-globenewswire 2024-12-09T18:05:53+00:00 weekly 0.7 https://trial.medpath.com/news/eu-decision-time-for-orphans-acoramidis-garadacimab-imetelstat-plus-10-other-products 2024-12-09T17:23:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eu-decision-time-for-orphans-acoramidis-garadacimab-imetelstat-plus-10-other-products 2024-12-09T17:23:33+00:00 weekly 0.7 https://trial.medpath.com/news/two-data-analyses-from-clinical-trials-show-epcoritamab-duobody-r-cd3xcd20 2024-12-09T17:07:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/two-data-analyses-from-clinical-trials-show-epcoritamab-duobody-r-cd3xcd20 2024-12-09T17:07:53+00:00 weekly 0.7 https://trial.medpath.com/news/tandem-non-cryopreserved-car-t-exhibits-favorable-activity-in-advanced-dlbcl-healio 2024-12-09T16:55:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tandem-non-cryopreserved-car-t-exhibits-favorable-activity-in-advanced-dlbcl-healio 2024-12-09T16:55:25+00:00 weekly 0.7 https://trial.medpath.com/news/filling-out-the-roadmap-for-faster-drug-approvals-inventum 2024-12-09T16:43:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/filling-out-the-roadmap-for-faster-drug-approvals-inventum 2024-12-09T16:43:28+00:00 weekly 0.7 https://trial.medpath.com/news/simple-hysterectomy-not-inferior-to-radical-hysterectomy-for-cervical-cancer-treatment 2024-12-09T16:25:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/simple-hysterectomy-not-inferior-to-radical-hysterectomy-for-cervical-cancer-treatment 2024-12-09T16:25:20+00:00 weekly 0.7 https://trial.medpath.com/news/four-therapies-that-may-treat-kennedy-s-disease-brain-and-life-magazine 2024-12-09T16:24:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/four-therapies-that-may-treat-kennedy-s-disease-brain-and-life-magazine 2024-12-09T16:24:03+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-ind-approval-to-base-therapeutics-base-edited-nk-cell-therapy-powered-by 2024-12-09T16:14:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-ind-approval-to-base-therapeutics-base-edited-nk-cell-therapy-powered-by 2024-12-09T16:14:59+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-and-safety-of-lenvatinib-plus-gefitinib-in-lenvatinib-resistant-hepatocellular-carcinomas 2024-12-09T15:43:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/efficacy-and-safety-of-lenvatinib-plus-gefitinib-in-lenvatinib-resistant-hepatocellular-carcinomas 2024-12-09T15:43:23+00:00 weekly 0.7 https://trial.medpath.com/news/interim-update-from-vico-therapeutics-on-their-cag-targeting-drug-vo659-hdbuzz 2024-12-09T15:41:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/interim-update-from-vico-therapeutics-on-their-cag-targeting-drug-vo659-hdbuzz 2024-12-09T15:41:17+00:00 weekly 0.7 https://trial.medpath.com/news/high-fiber-diets-may-reduce-risk-of-gvhd-after-bone-marrow-stem-cell-transplants 2024-12-09T15:40:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/high-fiber-diets-may-reduce-risk-of-gvhd-after-bone-marrow-stem-cell-transplants 2024-12-09T15:40:57+00:00 weekly 0.7 https://trial.medpath.com/news/stereotaxis-wins-approval-in-china-for-magnetic-ablation-catheter-massdevice 2024-12-09T15:35:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stereotaxis-wins-approval-in-china-for-magnetic-ablation-catheter-massdevice 2024-12-09T15:35:57+00:00 weekly 0.7 https://trial.medpath.com/news/tiakis-biotech-ag-reports-clinical-phase-ib-ii-trial-globenewswire 2024-12-09T15:01:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tiakis-biotech-ag-reports-clinical-phase-ib-ii-trial-globenewswire 2024-12-09T15:01:43+00:00 weekly 0.7 https://trial.medpath.com/news/modus-therapeutics-initiates-phase-ii-study-with-sevuparin-for-the-treatment-of-chronic-placera 2024-12-09T14:56:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/modus-therapeutics-initiates-phase-ii-study-with-sevuparin-for-the-treatment-of-chronic-placera 2024-12-09T14:56:52+00:00 weekly 0.7 https://trial.medpath.com/news/rural-pharmacists-face-mounting-challenges-expert-highlights-critical-workforce-and-safety-concerns 2024-12-09T14:50:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rural-pharmacists-face-mounting-challenges-expert-highlights-critical-workforce-and-safety-concerns 2024-12-09T14:50:43+00:00 weekly 0.7 https://trial.medpath.com/news/bionomics-publishes-the-positive-results-from-the-phase-2-attune-study-of-bnc210-biospace 2024-12-09T14:44:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bionomics-publishes-the-positive-results-from-the-phase-2-attune-study-of-bnc210-biospace 2024-12-09T14:44:29+00:00 weekly 0.7 https://trial.medpath.com/news/first-subject-dosed-in-initial-cohort-of-phase-2b-clinical-study-of-cyanvac-s-intranasal-biospace 2024-12-09T14:43:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-subject-dosed-in-initial-cohort-of-phase-2b-clinical-study-of-cyanvac-s-intranasal-biospace 2024-12-09T14:43:54+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-drug-succeeds-in-another-parkinson-s-trial-stat-news 2024-12-09T14:25:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-drug-succeeds-in-another-parkinson-s-trial-stat-news 2024-12-09T14:25:06+00:00 weekly 0.7 https://trial.medpath.com/news/gene-therapy-uptake-in-sickle-cell-stays-slow-despite-patient-interest-biopharma-dive 2024-12-09T14:20:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gene-therapy-uptake-in-sickle-cell-stays-slow-despite-patient-interest-biopharma-dive 2024-12-09T14:20:34+00:00 weekly 0.7 https://trial.medpath.com/news/early-signs-of-efficacy-for-a-novel-drug-and-a-new-predictive-tool-to-guide-patient-care 2024-12-09T14:19:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/early-signs-of-efficacy-for-a-novel-drug-and-a-new-predictive-tool-to-guide-patient-care 2024-12-09T14:19:27+00:00 weekly 0.7 https://trial.medpath.com/news/relmada-halts-depression-drug-trials-shifts-focus-to-psilocybin-program-amid-review 2024-12-09T14:13:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/relmada-halts-depression-drug-trials-shifts-focus-to-psilocybin-program-amid-review 2024-12-09T14:13:37+00:00 weekly 0.7 https://trial.medpath.com/news/woolsey-pharmaceuticals-reveals-breakthrough-findings-showing-spread-of-toxic-tdp-43 2024-12-09T14:02:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/woolsey-pharmaceuticals-reveals-breakthrough-findings-showing-spread-of-toxic-tdp-43 2024-12-09T14:02:49+00:00 weekly 0.7 https://trial.medpath.com/news/setpoint-medical-announces-filing-of-premarket-approval-pma-application-to-the-u-s 2024-12-09T13:55:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/setpoint-medical-announces-filing-of-premarket-approval-pma-application-to-the-u-s 2024-12-09T13:55:37+00:00 weekly 0.7 https://trial.medpath.com/news/novel-combination-studied-in-hpv16-positive-relapsed-or-metastatic-head-and-neck 2024-12-09T13:49:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-combination-studied-in-hpv16-positive-relapsed-or-metastatic-head-and-neck 2024-12-09T13:49:05+00:00 weekly 0.7 https://trial.medpath.com/news/vikram-narayan-md-on-cystectomy-outcomes-in-nadofaragene-treated-patients 2024-12-09T13:39:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vikram-narayan-md-on-cystectomy-outcomes-in-nadofaragene-treated-patients 2024-12-09T13:39:20+00:00 weekly 0.7 https://trial.medpath.com/news/serial-ctdna-to-understand-parpi-resistance-nature-reviews-urology 2024-12-09T13:38:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/serial-ctdna-to-understand-parpi-resistance-nature-reviews-urology 2024-12-09T13:38:22+00:00 weekly 0.7 https://trial.medpath.com/news/new-uk-swiss-bilateral-funding-for-clinical-trials-to-open-in-2025-nihr 2024-12-09T13:31:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-uk-swiss-bilateral-funding-for-clinical-trials-to-open-in-2025-nihr 2024-12-09T13:31:38+00:00 weekly 0.7 https://trial.medpath.com/news/first-fda-approved-treatment-for-severe-frostbite-now-commercially-available-in-the-us 2024-12-09T13:25:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-fda-approved-treatment-for-severe-frostbite-now-commercially-available-in-the-us 2024-12-09T13:25:23+00:00 weekly 0.7 https://trial.medpath.com/news/lomond-therapeutics-reports-results-from-ongoing-clinical-studies-of 2024-12-09T13:19:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lomond-therapeutics-reports-results-from-ongoing-clinical-studies-of 2024-12-09T13:19:45+00:00 weekly 0.7 https://trial.medpath.com/news/crinetics-breakthrough-oral-acromegaly-drug-advances-as-fda-accepts-nda-for-stock-titan 2024-12-09T13:10:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/crinetics-breakthrough-oral-acromegaly-drug-advances-as-fda-accepts-nda-for-stock-titan 2024-12-09T13:10:03+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-s-parkinson-s-drug-tavapadon-shows-breakthrough-results-in-phase-3-trial-stock-titan 2024-12-09T13:09:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-s-parkinson-s-drug-tavapadon-shows-breakthrough-results-in-phase-3-trial-stock-titan 2024-12-09T13:09:37+00:00 weekly 0.7 https://trial.medpath.com/news/acurx-updates-phase-3-readiness-for-ibezapolstat-in-c-difficile-infection-based-on-recent 2024-12-09T13:04:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acurx-updates-phase-3-readiness-for-ibezapolstat-in-c-difficile-infection-based-on-recent 2024-12-09T13:04:30+00:00 weekly 0.7 https://trial.medpath.com/news/meiragtx-granted-fda-regenerative-medicine-advanced-therapy-globenewswire 2024-12-09T13:02:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/meiragtx-granted-fda-regenerative-medicine-advanced-therapy-globenewswire 2024-12-09T13:02:24+00:00 weekly 0.7 https://trial.medpath.com/news/artivion-granted-fda-humanitarian-device-exemption-for-the-amds-hybrid-prosthesis 2024-12-09T13:01:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/artivion-granted-fda-humanitarian-device-exemption-for-the-amds-hybrid-prosthesis 2024-12-09T13:01:10+00:00 weekly 0.7 https://trial.medpath.com/news/cantex-scores-third-fda-orphan-drug-win-for-breakthrough-breast-cancer-brain 2024-12-09T12:41:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cantex-scores-third-fda-orphan-drug-win-for-breakthrough-breast-cancer-brain 2024-12-09T12:41:15+00:00 weekly 0.7 https://trial.medpath.com/news/adc-therapeutics-zynlonta-shows-breakthrough-97-response-rate-in-lymphoma 2024-12-09T12:31:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adc-therapeutics-zynlonta-shows-breakthrough-97-response-rate-in-lymphoma 2024-12-09T12:31:46+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-status-to-seres-infection-drug-investing-com 2024-12-09T12:29:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-breakthrough-status-to-seres-infection-drug-investing-com 2024-12-09T12:29:51+00:00 weekly 0.7 https://trial.medpath.com/news/chiesi-global-rare-diseases-and-protalix-biotherapeutics-announce-validation-of-pr-newswire 2024-12-09T12:18:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chiesi-global-rare-diseases-and-protalix-biotherapeutics-announce-validation-of-pr-newswire 2024-12-09T12:18:57+00:00 weekly 0.7 https://trial.medpath.com/news/aiviva-biopharma-receives-fda-clearance-to-administer-aiv001-in-facial-skin-yahoo-finance 2024-12-09T12:15:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aiviva-biopharma-receives-fda-clearance-to-administer-aiv001-in-facial-skin-yahoo-finance 2024-12-09T12:15:03+00:00 weekly 0.7 https://trial.medpath.com/news/olema-pharma-s-novel-cancer-drug-op-3136-secures-fda-clearance-for-clinical-trials 2024-12-09T12:09:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/olema-pharma-s-novel-cancer-drug-op-3136-secures-fda-clearance-for-clinical-trials 2024-12-09T12:09:34+00:00 weekly 0.7 https://trial.medpath.com/news/nuvalent-appoints-grant-bogle-to-board-of-directors-citybiz 2024-12-09T12:00:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nuvalent-appoints-grant-bogle-to-board-of-directors-citybiz 2024-12-09T12:00:50+00:00 weekly 0.7 https://trial.medpath.com/news/supriya-lifescience-gets-brazil-approval-for-mental-illness-drug-files-patent-for-heart 2024-12-09T11:48:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/supriya-lifescience-gets-brazil-approval-for-mental-illness-drug-files-patent-for-heart 2024-12-09T11:48:58+00:00 weekly 0.7 https://trial.medpath.com/news/merck-announces-phase-3-keylynk-001-trial-met-primary-endpoint-of-progression-free 2024-12-09T11:47:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-announces-phase-3-keylynk-001-trial-met-primary-endpoint-of-progression-free 2024-12-09T11:47:15+00:00 weekly 0.7 https://trial.medpath.com/news/angiodynamics-receives-fda-clearance-for-the-nanoknife-r-system-for-prostate-tissue-ablation 2024-12-09T11:10:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/angiodynamics-receives-fda-clearance-for-the-nanoknife-r-system-for-prostate-tissue-ablation 2024-12-09T11:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/ideaya-biosciences-unveils-ide892-breakthrough-cancer-drug-candidate-with-promising 2024-12-09T11:09:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ideaya-biosciences-unveils-ide892-breakthrough-cancer-drug-candidate-with-promising 2024-12-09T11:09:50+00:00 weekly 0.7 https://trial.medpath.com/news/cspc-pharmaceutical-s-breast-cancer-drug-gains-approval-tipranks-com 2024-12-09T10:23:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cspc-pharmaceutical-s-breast-cancer-drug-gains-approval-tipranks-com 2024-12-09T10:23:07+00:00 weekly 0.7 https://trial.medpath.com/news/rapport-therapeutics-presents-data-demonstrating-consistent-association-between-biospace 2024-12-09T10:17:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rapport-therapeutics-presents-data-demonstrating-consistent-association-between-biospace 2024-12-09T10:17:11+00:00 weekly 0.7 https://trial.medpath.com/news/biomerieux-gains-fda-clearance-for-tropical-fever-test-markets-insider 2024-12-09T09:55:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biomerieux-gains-fda-clearance-for-tropical-fever-test-markets-insider 2024-12-09T09:55:11+00:00 weekly 0.7 https://trial.medpath.com/news/cd40-targeted-therapies-clinical-trials-market-globenewswire 2024-12-09T09:49:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cd40-targeted-therapies-clinical-trials-market-globenewswire 2024-12-09T09:49:40+00:00 weekly 0.7 https://trial.medpath.com/news/liquid-biopsies-emerge-as-game-changer-in-precision-oncology-testing-expert-highlights-value-based-care-impact 2024-12-09T09:18:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/liquid-biopsies-emerge-as-game-changer-in-precision-oncology-testing-expert-highlights-value-based-care-impact 2024-12-09T09:18:53+00:00 weekly 0.7 https://trial.medpath.com/news/cytrill-bv-raises-eur85m-in-series-b-financing-european-biotechnology-magazine 2024-12-09T09:16:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cytrill-bv-raises-eur85m-in-series-b-financing-european-biotechnology-magazine 2024-12-09T09:16:21+00:00 weekly 0.7 https://trial.medpath.com/news/hemogenyx-advances-clinical-trial-for-aml-treatment-tipranks-com 2024-12-09T07:59:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hemogenyx-advances-clinical-trial-for-aml-treatment-tipranks-com 2024-12-09T07:59:26+00:00 weekly 0.7 https://trial.medpath.com/news/us-fda-accepts-gsk-s-submission-for-the-use-of-nucala-mepolizumab-in-copd-gsk 2024-12-09T07:03:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/us-fda-accepts-gsk-s-submission-for-the-use-of-nucala-mepolizumab-in-copd-gsk 2024-12-09T07:03:41+00:00 weekly 0.7 https://trial.medpath.com/news/celltrion-gets-approval-of-omlyclo-in-canada-ked-global 2024-12-09T07:02:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/celltrion-gets-approval-of-omlyclo-in-canada-ked-global 2024-12-09T07:02:21+00:00 weekly 0.7 https://trial.medpath.com/news/be-biopharma-unveils-become-9-trial-and-presents-on-versatile-b-cell-medicines-platform 2024-12-09T06:06:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/be-biopharma-unveils-become-9-trial-and-presents-on-versatile-b-cell-medicines-platform 2024-12-09T06:06:00+00:00 weekly 0.7 https://trial.medpath.com/news/aspc-congress-2024-ai-glp-1s-and-novel-imaging-reshape-cardiovascular-disease-prevention 2024-12-09T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aspc-congress-2024-ai-glp-1s-and-novel-imaging-reshape-cardiovascular-disease-prevention 2024-12-09T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-supply-chain-integration-critical-for-protocol-success-experts-emphasize 2024-12-09T05:50:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-supply-chain-integration-critical-for-protocol-success-experts-emphasize 2024-12-09T05:50:38+00:00 weekly 0.7 https://trial.medpath.com/news/paradigm-raises-16m-for-phase-iii-trial-of-knee-osteoarthritis-treatment-stockhead 2024-12-09T05:47:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/paradigm-raises-16m-for-phase-iii-trial-of-knee-osteoarthritis-treatment-stockhead 2024-12-09T05:47:23+00:00 weekly 0.7 https://trial.medpath.com/news/ms-pharma-becomes-partner-for-the-commercialization-of-fyb202-ustekinumab-in-eqs-news 2024-12-09T05:33:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ms-pharma-becomes-partner-for-the-commercialization-of-fyb202-ustekinumab-in-eqs-news 2024-12-09T05:33:07+00:00 weekly 0.7 https://trial.medpath.com/news/fda-action-alert-ionis-lexicon-astrazeneca-daiichi-sankyo-and-more-biospace 2024-12-09T05:22:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-action-alert-ionis-lexicon-astrazeneca-daiichi-sankyo-and-more-biospace 2024-12-09T05:22:09+00:00 weekly 0.7 https://trial.medpath.com/news/evidence-mounts-for-potential-of-glp-1s-in-alzheimer-s-disease-biospace 2024-12-09T05:04:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evidence-mounts-for-potential-of-glp-1s-in-alzheimer-s-disease-biospace 2024-12-09T05:04:49+00:00 weekly 0.7 https://trial.medpath.com/news/syneos-health-announces-webinar-on-healthcare-innovation-and-digital-transformation-trends-for-2025 2024-12-09T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/syneos-health-announces-webinar-on-healthcare-innovation-and-digital-transformation-trends-for-2025 2024-12-09T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bridging-clinical-research-and-clinical-care-with-ai-aiding-pathologists-tool 2024-12-09T04:34:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bridging-clinical-research-and-clinical-care-with-ai-aiding-pathologists-tool 2024-12-09T04:34:00+00:00 weekly 0.7 https://trial.medpath.com/news/china-medical-system-first-prescriptions-for-innovative-drug-lumeblue-r-issued-in-china 2024-12-09T04:07:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/china-medical-system-first-prescriptions-for-innovative-drug-lumeblue-r-issued-in-china 2024-12-09T04:07:50+00:00 weekly 0.7 https://trial.medpath.com/news/arcellx-s-multiple-myeloma-treatment-shows-breakthrough-97-response-rate-in-phase-2-trial 2024-12-09T04:04:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arcellx-s-multiple-myeloma-treatment-shows-breakthrough-97-response-rate-in-phase-2-trial 2024-12-09T04:04:45+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-disease-pipeline-drugs-2024-clinical-trials-ema-openpr-com 2024-12-09T03:49:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzheimer-s-disease-pipeline-drugs-2024-clinical-trials-ema-openpr-com 2024-12-09T03:49:07+00:00 weekly 0.7 https://trial.medpath.com/news/european-commission-approves-novo-holdings-16-5b-catalent-acquisition 2024-12-09T03:17:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-commission-approves-novo-holdings-16-5b-catalent-acquisition 2024-12-09T03:17:45+00:00 weekly 0.7 https://trial.medpath.com/news/odronextamab-ash-presentations-underscore-impressive-potential-in-earlier-lines-of-treatment-and-additional-types-of-lymphoma 2024-12-09T03:12:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/odronextamab-ash-presentations-underscore-impressive-potential-in-earlier-lines-of-treatment-and-additional-types-of-lymphoma 2024-12-09T03:12:43+00:00 weekly 0.7 https://trial.medpath.com/news/sk-biopharmaceuticals-unveils-phase-3-cenobamate-results-in-northeast-asian-epilepsy 2024-12-09T02:59:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sk-biopharmaceuticals-unveils-phase-3-cenobamate-results-in-northeast-asian-epilepsy 2024-12-09T02:59:42+00:00 weekly 0.7 https://trial.medpath.com/news/dr-foster-on-daratumumab-plus-lenalidomide-in-newly-diagnosed-myeloma-after-transplant 2024-12-09T02:57:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-foster-on-daratumumab-plus-lenalidomide-in-newly-diagnosed-myeloma-after-transplant 2024-12-09T02:57:45+00:00 weekly 0.7 https://trial.medpath.com/news/us-real-world-analysis-supports-clinical-benefit-of-tafasitamab-in-r-r-dlbcl-onclive 2024-12-09T02:41:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/us-real-world-analysis-supports-clinical-benefit-of-tafasitamab-in-r-r-dlbcl-onclive 2024-12-09T02:41:36+00:00 weekly 0.7 https://trial.medpath.com/news/fs118-showcases-modest-efficacy-in-relapsed-refractory-dlbcl-onclive 2024-12-09T01:56:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fs118-showcases-modest-efficacy-in-relapsed-refractory-dlbcl-onclive 2024-12-09T01:56:30+00:00 weekly 0.7 https://trial.medpath.com/news/puberty-blockers-can-a-drug-trial-solve-the-big-debate-bbc 2024-12-09T01:35:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/puberty-blockers-can-a-drug-trial-solve-the-big-debate-bbc 2024-12-09T01:35:09+00:00 weekly 0.7 https://trial.medpath.com/news/disc-medicine-s-myelofibrosis-drug-shows-breakthrough-results-in-phase-1b-trial-with-100 2024-12-09T01:14:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/disc-medicine-s-myelofibrosis-drug-shows-breakthrough-results-in-phase-1b-trial-with-100 2024-12-09T01:14:36+00:00 weekly 0.7 https://trial.medpath.com/news/genomic-landscape-of-circulating-tumor-dna-in-her2-low-metastatic-breast-cancer-nature 2024-12-09T01:08:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genomic-landscape-of-circulating-tumor-dna-in-her2-low-metastatic-breast-cancer-nature 2024-12-09T01:08:28+00:00 weekly 0.7 https://trial.medpath.com/news/maintenance-teclistamab-yields-preliminary-activity-in-ndmm-cancer-network 2024-12-09T00:47:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maintenance-teclistamab-yields-preliminary-activity-in-ndmm-cancer-network 2024-12-09T00:47:19+00:00 weekly 0.7 https://trial.medpath.com/news/agios-phase-3-trial-breakthrough-mitapivat-shows-3x-better-results-for-thalassemia-treatment 2024-12-09T00:33:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/agios-phase-3-trial-breakthrough-mitapivat-shows-3x-better-results-for-thalassemia-treatment 2024-12-09T00:33:34+00:00 weekly 0.7 https://trial.medpath.com/news/pharma-s-memorable-moments-of-2024-c-en-american-chemical-society 2024-12-09T00:29:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharma-s-memorable-moments-of-2024-c-en-american-chemical-society 2024-12-09T00:29:25+00:00 weekly 0.7 https://trial.medpath.com/news/actinogen-medical-expands-alzheimer-s-drug-trial-to-us 2024-12-09T00:27:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/actinogen-medical-expands-alzheimer-s-drug-trial-to-us 2024-12-09T00:27:44+00:00 weekly 0.7 https://trial.medpath.com/news/innovent-presents-updated-data-from-innovative-anti-cldn18-2-adc-ibi343-phase-1 2024-12-09T00:15:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innovent-presents-updated-data-from-innovative-anti-cldn18-2-adc-ibi343-phase-1 2024-12-09T00:15:03+00:00 weekly 0.7 https://trial.medpath.com/news/key-fda-approvals-in-2024-c-en 2024-12-09T00:07:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/key-fda-approvals-in-2024-c-en 2024-12-09T00:07:42+00:00 weekly 0.7 https://trial.medpath.com/news/aptose-clinical-data-featured-in-poster-presentation-at-the-2024-ash-annual-meeting-support-tuspetinib-triple-drug-therapy-for-newly-diagnosed-aml 2024-12-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aptose-clinical-data-featured-in-poster-presentation-at-the-2024-ash-annual-meeting-support-tuspetinib-triple-drug-therapy-for-newly-diagnosed-aml 2024-12-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/iopofosine-i-131-shows-promising-results-in-previously-treated-waldenstrom-macroglobulinemia-patients 2024-12-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iopofosine-i-131-shows-promising-results-in-previously-treated-waldenstrom-macroglobulinemia-patients 2024-12-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/endometriosis-research-faces-funding-hurdles-despite-affecting-10-of-women-globally 2024-12-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/endometriosis-research-faces-funding-hurdles-despite-affecting-10-of-women-globally 2024-12-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/promising-results-for-disitamab-vedotin-plus-toripalimab-in-locally-advanced-or-metastatic-urothelial-carcinoma 2024-12-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/promising-results-for-disitamab-vedotin-plus-toripalimab-in-locally-advanced-or-metastatic-urothelial-carcinoma 2024-12-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/glp-1-agonists-market-2034-clinical-trials-ema-pdma-fda-approvals-target-population-companies-delveinsight 2024-12-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glp-1-agonists-market-2034-clinical-trials-ema-pdma-fda-approvals-target-population-companies-delveinsight 2024-12-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/batten-disease-research-updates-with-dr-ineka-whiteman 2024-12-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/batten-disease-research-updates-with-dr-ineka-whiteman 2024-12-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/anlotinib-plus-chemotherapy-as-a-first-line-treatment-for-gastrointestinal-cancer-patients-with 2024-12-08T23:35:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/anlotinib-plus-chemotherapy-as-a-first-line-treatment-for-gastrointestinal-cancer-patients-with 2024-12-08T23:35:10+00:00 weekly 0.7 https://trial.medpath.com/news/zilovertamab-vedotin-r-chp-elicits-high-complete-response-rate-in-dlbcl 2024-12-08T23:32:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zilovertamab-vedotin-r-chp-elicits-high-complete-response-rate-in-dlbcl 2024-12-08T23:32:27+00:00 weekly 0.7 https://trial.medpath.com/news/molecular-partners-presents-clinical-data-supporting-its-ongoing-mp0533-study-quantisnow 2024-12-08T23:12:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/molecular-partners-presents-clinical-data-supporting-its-ongoing-mp0533-study-quantisnow 2024-12-08T23:12:09+00:00 weekly 0.7 https://trial.medpath.com/news/aes-poster-provides-safety-insights-to-antiseizure-medication-fenfluramine-neurologylive 2024-12-08T23:10:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aes-poster-provides-safety-insights-to-antiseizure-medication-fenfluramine-neurologylive 2024-12-08T23:10:12+00:00 weekly 0.7 https://trial.medpath.com/news/vertex-presents-positive-long-term-data-on-casgevytm-exagamglogene-autotemcel-at 2024-12-08T23:03:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vertex-presents-positive-long-term-data-on-casgevytm-exagamglogene-autotemcel-at 2024-12-08T23:03:41+00:00 weekly 0.7 https://trial.medpath.com/news/dr-mauz-koerholz-on-the-role-of-pembrolizumab-in-younger-patients-with-low-risk 2024-12-08T23:02:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-mauz-koerholz-on-the-role-of-pembrolizumab-in-younger-patients-with-low-risk 2024-12-08T23:02:34+00:00 weekly 0.7 https://trial.medpath.com/news/positive-efficacy-and-safety-outcomes-result-from-second-line-liso-cel-in-lbcl 2024-12-08T22:47:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/positive-efficacy-and-safety-outcomes-result-from-second-line-liso-cel-in-lbcl 2024-12-08T22:47:30+00:00 weekly 0.7 https://trial.medpath.com/news/navtemadlin-monotherapy-shows-improvements-in-hallmarks-of-r-r-myelofibrosis 2024-12-08T22:37:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/navtemadlin-monotherapy-shows-improvements-in-hallmarks-of-r-r-myelofibrosis 2024-12-08T22:37:20+00:00 weekly 0.7 https://trial.medpath.com/news/novel-ptsd-treatment-improved-symptom-severity-in-phase-iib-trial-medpage-today 2024-12-08T22:17:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-ptsd-treatment-improved-symptom-severity-in-phase-iib-trial-medpage-today 2024-12-08T22:17:32+00:00 weekly 0.7 https://trial.medpath.com/news/preventing-vocs-in-people-with-sickle-cell-disease-with-exa-cel-gene-editing-therapy 2024-12-08T21:47:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/preventing-vocs-in-people-with-sickle-cell-disease-with-exa-cel-gene-editing-therapy 2024-12-08T21:47:03+00:00 weekly 0.7 https://trial.medpath.com/news/asciminib-continues-to-best-soc-tkis-as-secondary-end-points-of-asc4first-trial-are-met 2024-12-08T21:26:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/asciminib-continues-to-best-soc-tkis-as-secondary-end-points-of-asc4first-trial-are-met 2024-12-08T21:26:36+00:00 weekly 0.7 https://trial.medpath.com/news/brexu-cel-displays-comparable-efficacy-across-age-groups-in-relapsed-refractory-b-all 2024-12-08T21:26:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/brexu-cel-displays-comparable-efficacy-across-age-groups-in-relapsed-refractory-b-all 2024-12-08T21:26:34+00:00 weekly 0.7 https://trial.medpath.com/news/olverembatinib-may-be-effective-in-second-line-for-cp-cml-onclive 2024-12-08T21:11:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/olverembatinib-may-be-effective-in-second-line-for-cp-cml-onclive 2024-12-08T21:11:11+00:00 weekly 0.7 https://trial.medpath.com/news/beam-therapeutics-presents-new-non-human-primate-nhp-data-demonstrating-proof-of 2024-12-08T20:57:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/beam-therapeutics-presents-new-non-human-primate-nhp-data-demonstrating-proof-of 2024-12-08T20:57:54+00:00 weekly 0.7 https://trial.medpath.com/news/new-clinical-trial-hopes-to-find-gold-standard-for-staging-lobular-breast-cancer 2024-12-08T20:30:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-clinical-trial-hopes-to-find-gold-standard-for-staging-lobular-breast-cancer 2024-12-08T20:30:15+00:00 weekly 0.7 https://trial.medpath.com/news/merck-s-cancer-drug-achieves-100-complete-response-rate-in-phase-2-lymphoma-trial 2024-12-08T20:13:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-s-cancer-drug-achieves-100-complete-response-rate-in-phase-2-lymphoma-trial 2024-12-08T20:13:04+00:00 weekly 0.7 https://trial.medpath.com/news/dr-kaddoura-on-genomic-determinants-of-outcomes-in-igh-ccnd1-myeloma-treated-onclive 2024-12-08T20:10:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-kaddoura-on-genomic-determinants-of-outcomes-in-igh-ccnd1-myeloma-treated-onclive 2024-12-08T20:10:48+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-reports-positive-results-from-amplify-phase-3-trial-tipranks-com 2024-12-08T20:02:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-reports-positive-results-from-amplify-phase-3-trial-tipranks-com 2024-12-08T20:02:15+00:00 weekly 0.7 https://trial.medpath.com/news/healy-center-for-als-presents-the-lalji-award-for-innovative-healing 2024-12-08T19:47:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/healy-center-for-als-presents-the-lalji-award-for-innovative-healing 2024-12-08T19:47:51+00:00 weekly 0.7 https://trial.medpath.com/news/conduct-phase-iii-clinical-study-on-resistant-hypertension-cdsco-panel-tells-sun 2024-12-08T18:22:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/conduct-phase-iii-clinical-study-on-resistant-hypertension-cdsco-panel-tells-sun 2024-12-08T18:22:17+00:00 weekly 0.7 https://trial.medpath.com/news/mitsubishi-tanabe-pharma-america-to-present-data-on-investigational-nd0612-at-the-2024 2024-12-08T17:58:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mitsubishi-tanabe-pharma-america-to-present-data-on-investigational-nd0612-at-the-2024 2024-12-08T17:58:22+00:00 weekly 0.7 https://trial.medpath.com/news/five-year-results-confirm-genentech-s-polivy-combination-therapy-as-new-standard-of 2024-12-08T17:53:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/five-year-results-confirm-genentech-s-polivy-combination-therapy-as-new-standard-of 2024-12-08T17:53:45+00:00 weekly 0.7 https://trial.medpath.com/news/kite-presents-new-data-underscoring-curative-potential-of-yescarta-r-in-relapsed-quantisnow 2024-12-08T17:42:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kite-presents-new-data-underscoring-curative-potential-of-yescarta-r-in-relapsed-quantisnow 2024-12-08T17:42:11+00:00 weekly 0.7 https://trial.medpath.com/news/tecvayli-r-teclistamab-cqyv-demonstrates-potential-as-frontline-combination-therapy-for 2024-12-08T17:39:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tecvayli-r-teclistamab-cqyv-demonstrates-potential-as-frontline-combination-therapy-for 2024-12-08T17:39:46+00:00 weekly 0.7 https://trial.medpath.com/news/roswell-park-experts-report-insights-on-car-t-for-follicular-lymphoma-keynote-667 2024-12-08T17:33:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roswell-park-experts-report-insights-on-car-t-for-follicular-lymphoma-keynote-667 2024-12-08T17:33:15+00:00 weekly 0.7 https://trial.medpath.com/news/cogent-biosciences-announces-positive-updated-data-from-ongoing-phase-2-apex-trial 2024-12-08T17:12:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cogent-biosciences-announces-positive-updated-data-from-ongoing-phase-2-apex-trial 2024-12-08T17:12:10+00:00 weekly 0.7 https://trial.medpath.com/news/antibody-shows-encouraging-results-for-treating-high-risk-follicular-lymphoma-and 2024-12-08T17:01:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/antibody-shows-encouraging-results-for-treating-high-risk-follicular-lymphoma-and 2024-12-08T17:01:10+00:00 weekly 0.7 https://trial.medpath.com/news/darzalex-r-daratumumab-subcutaneous-formulation-shows-51-globenewswire 2024-12-08T16:33:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/darzalex-r-daratumumab-subcutaneous-formulation-shows-51-globenewswire 2024-12-08T16:33:08+00:00 weekly 0.7 https://trial.medpath.com/news/multi-center-study-shows-education-level-income-impact-access-to-stem-cell-transplantation 2024-12-08T16:28:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/multi-center-study-shows-education-level-income-impact-access-to-stem-cell-transplantation 2024-12-08T16:28:37+00:00 weekly 0.7 https://trial.medpath.com/news/combining-bcl-2-and-btk-inhibitors-shows-promise-in-cll-dana-farber-cancer-institute 2024-12-08T16:17:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/combining-bcl-2-and-btk-inhibitors-shows-promise-in-cll-dana-farber-cancer-institute 2024-12-08T16:17:47+00:00 weekly 0.7 https://trial.medpath.com/news/fixed-duration-calquence-plus-venetoclax-demonstrated-superior-pfs-vs-standard-of-care 2024-12-08T16:06:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fixed-duration-calquence-plus-venetoclax-demonstrated-superior-pfs-vs-standard-of-care 2024-12-08T16:06:17+00:00 weekly 0.7 https://trial.medpath.com/news/studies-highlight-progress-in-preventing-and-treating-blood-cancers-and-pre-cancerous-conditions 2024-12-08T16:04:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/studies-highlight-progress-in-preventing-and-treating-blood-cancers-and-pre-cancerous-conditions 2024-12-08T16:04:54+00:00 weekly 0.7 https://trial.medpath.com/news/lymphoma-immunotherapy-enhanced-by-enzyme-inhibitor-in-preclinical-model-prompting 2024-12-08T15:16:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lymphoma-immunotherapy-enhanced-by-enzyme-inhibitor-in-preclinical-model-prompting 2024-12-08T15:16:04+00:00 weekly 0.7 https://trial.medpath.com/news/maxx-orthopedics-announces-fda-clearance-of-medial-congruent-insert-for-tka-system 2024-12-08T15:14:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maxx-orthopedics-announces-fda-clearance-of-medial-congruent-insert-for-tka-system 2024-12-08T15:14:08+00:00 weekly 0.7 https://trial.medpath.com/news/dr-jurczak-on-the-efficacy-and-safety-of-nemtabrutinib-in-r-r-follicular-lymphoma 2024-12-08T15:10:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-jurczak-on-the-efficacy-and-safety-of-nemtabrutinib-in-r-r-follicular-lymphoma 2024-12-08T15:10:30+00:00 weekly 0.7 https://trial.medpath.com/news/hydroxyurea-shows-clinical-benefit-in-hbsc-misses-the-mark-on-safety-hcplive 2024-12-08T14:31:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hydroxyurea-shows-clinical-benefit-in-hbsc-misses-the-mark-on-safety-hcplive 2024-12-08T14:31:59+00:00 weekly 0.7 https://trial.medpath.com/news/abbisko-cayman-reports-promising-cgvhd-drug-results-markets-insider 2024-12-08T14:31:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbisko-cayman-reports-promising-cgvhd-drug-results-markets-insider 2024-12-08T14:31:53+00:00 weekly 0.7 https://trial.medpath.com/news/countdown-to-neo-brain-computer-interface-clinical-trial-in-china 2024-12-08T14:31:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/countdown-to-neo-brain-computer-interface-clinical-trial-in-china 2024-12-08T14:31:26+00:00 weekly 0.7 https://trial.medpath.com/news/covid-19-vaccination-effective-in-preventing-long-covid-in-young-people 2024-12-08T14:10:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/covid-19-vaccination-effective-in-preventing-long-covid-in-young-people 2024-12-08T14:10:06+00:00 weekly 0.7 https://trial.medpath.com/news/is-your-mind-ready-to-consider-investing-in-psychedelics-stocks 2024-12-08T13:04:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/is-your-mind-ready-to-consider-investing-in-psychedelics-stocks 2024-12-08T13:04:46+00:00 weekly 0.7 https://trial.medpath.com/news/ppbt-stock-surges-150-on-superior-efficacy-of-pdac-combo-therapy 2024-12-08T11:55:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ppbt-stock-surges-150-on-superior-efficacy-of-pdac-combo-therapy 2024-12-08T11:55:36+00:00 weekly 0.7 https://trial.medpath.com/news/commonly-prescribed-drugs-increase-dementia-risk-study-finds-surrey-live 2024-12-08T11:14:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/commonly-prescribed-drugs-increase-dementia-risk-study-finds-surrey-live 2024-12-08T11:14:17+00:00 weekly 0.7 https://trial.medpath.com/news/siamak-daneshmand-md-on-safety-tolerability-data-from-sunrise-1-urology-times 2024-12-08T11:03:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/siamak-daneshmand-md-on-safety-tolerability-data-from-sunrise-1-urology-times 2024-12-08T11:03:57+00:00 weekly 0.7 https://trial.medpath.com/news/ash-expert-axi-cel-treatment-causes-decreased-incidence-severity-of-toxicities-in-large 2024-12-08T10:54:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ash-expert-axi-cel-treatment-causes-decreased-incidence-severity-of-toxicities-in-large 2024-12-08T10:54:23+00:00 weekly 0.7 https://trial.medpath.com/news/regeneron-pharmaceuticals-releases-positive-phase-3-trial-data-for-poze-cemdi 2024-12-08T10:23:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regeneron-pharmaceuticals-releases-positive-phase-3-trial-data-for-poze-cemdi 2024-12-08T10:23:03+00:00 weekly 0.7 https://trial.medpath.com/news/ash-novo-s-etavopivat-for-sickle-cell-disease-cuts-voc-rates-in-half 2024-12-08T09:58:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ash-novo-s-etavopivat-for-sickle-cell-disease-cuts-voc-rates-in-half 2024-12-08T09:58:31+00:00 weekly 0.7 https://trial.medpath.com/news/biden-administration-s-access-model-offers-hope-for-cell-and-gene-therapies-forbes 2024-12-08T08:17:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biden-administration-s-access-model-offers-hope-for-cell-and-gene-therapies-forbes 2024-12-08T08:17:55+00:00 weekly 0.7 https://trial.medpath.com/news/receiving-asct-after-first-cr-may-improve-certain-outcomes-in-aml 2024-12-08T07:23:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/receiving-asct-after-first-cr-may-improve-certain-outcomes-in-aml 2024-12-08T07:23:08+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-advances-a-drug-for-a-rare-platelet-destroying-disease-stat-news 2024-12-08T05:21:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sanofi-advances-a-drug-for-a-rare-platelet-destroying-disease-stat-news 2024-12-08T05:21:36+00:00 weekly 0.7 https://trial.medpath.com/news/ketogenic-diet-and-b-hydroxybutyrate-may-enhance-car-t-cell-therapy-efficacy 2024-12-08T04:55:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ketogenic-diet-and-b-hydroxybutyrate-may-enhance-car-t-cell-therapy-efficacy 2024-12-08T04:55:26+00:00 weekly 0.7 https://trial.medpath.com/news/researchers-report-new-opportunities-to-improve-quality-of-life-for-people-with-pr-newswire 2024-12-08T04:31:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/researchers-report-new-opportunities-to-improve-quality-of-life-for-people-with-pr-newswire 2024-12-08T04:31:56+00:00 weekly 0.7 https://trial.medpath.com/news/oral-revumenib-based-combo-produces-responses-in-r-r-aml-onclive 2024-12-08T03:14:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oral-revumenib-based-combo-produces-responses-in-r-r-aml-onclive 2024-12-08T03:14:48+00:00 weekly 0.7 https://trial.medpath.com/news/scitech-development-welcomes-john-chapman-to-the-strategic-advisory-board-as-senior 2024-12-08T02:04:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scitech-development-welcomes-john-chapman-to-the-strategic-advisory-board-as-senior 2024-12-08T02:04:37+00:00 weekly 0.7 https://trial.medpath.com/news/promising-results-for-novel-triplet-therapy-in-high-risk-chronic-lymphocytic-leukemia 2024-12-08T01:51:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/promising-results-for-novel-triplet-therapy-in-high-risk-chronic-lymphocytic-leukemia 2024-12-08T01:51:07+00:00 weekly 0.7 https://trial.medpath.com/news/program-targets-poverty-to-improve-childhood-cancer-treatment 2024-12-08T00:42:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/program-targets-poverty-to-improve-childhood-cancer-treatment 2024-12-08T00:42:09+00:00 weekly 0.7 https://trial.medpath.com/news/investigational-epcoritamab-duobody-r-cd3xcd20-combination-therapy-shows-high 2024-12-08T00:39:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/investigational-epcoritamab-duobody-r-cd3xcd20-combination-therapy-shows-high 2024-12-08T00:39:32+00:00 weekly 0.7 https://trial.medpath.com/news/industry-updates-from-floretina-icoor-2024-ophthalmology-times-europe 2024-12-08T00:26:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/industry-updates-from-floretina-icoor-2024-ophthalmology-times-europe 2024-12-08T00:26:22+00:00 weekly 0.7 https://trial.medpath.com/news/novel-combination-of-pozelimab-and-cemdisiran-poze-cemdi-achieved-greater-control 2024-12-08T00:06:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-combination-of-pozelimab-and-cemdisiran-poze-cemdi-achieved-greater-control 2024-12-08T00:06:29+00:00 weekly 0.7 https://trial.medpath.com/news/news-and-events-aviceda-therapeutics 2024-12-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/news-and-events-aviceda-therapeutics 2024-12-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/adaptive-biotechnologies-announces-new-data-at-the-66th-ash-globenewswire 2024-12-07T23:35:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adaptive-biotechnologies-announces-new-data-at-the-66th-ash-globenewswire 2024-12-07T23:35:57+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trials-uganda-makes-major-advances-new-vision-official 2024-12-07T23:34:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trials-uganda-makes-major-advances-new-vision-official 2024-12-07T23:34:19+00:00 weekly 0.7 https://trial.medpath.com/news/galapagos-announces-encouraging-new-results-from-ongoing-phase-1-2-study-of-cd19 2024-12-07T23:20:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/galapagos-announces-encouraging-new-results-from-ongoing-phase-1-2-study-of-cd19 2024-12-07T23:20:40+00:00 weekly 0.7 https://trial.medpath.com/news/tandem-cd20-cd19-car-zamto-cel-shows-promise-in-dlbcl-cgtlive-r 2024-12-07T21:18:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tandem-cd20-cd19-car-zamto-cel-shows-promise-in-dlbcl-cgtlive-r 2024-12-07T21:18:49+00:00 weekly 0.7 https://trial.medpath.com/news/blincyto-r-blinatumomab-added-to-chemotherapy-significantly-amgen 2024-12-07T21:11:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/blincyto-r-blinatumomab-added-to-chemotherapy-significantly-amgen 2024-12-07T21:11:08+00:00 weekly 0.7 https://trial.medpath.com/news/rapcabtagene-autoleucel-shows-promise-for-dlbcl-in-updated-phase-2-data-cgtlive-r 2024-12-07T20:18:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rapcabtagene-autoleucel-shows-promise-for-dlbcl-in-updated-phase-2-data-cgtlive-r 2024-12-07T20:18:38+00:00 weekly 0.7 https://trial.medpath.com/news/uk-approves-pfizer-biontech-covid-19-vaccine-first-in-the-world-abs-cbn-news 2024-12-07T19:54:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uk-approves-pfizer-biontech-covid-19-vaccine-first-in-the-world-abs-cbn-news 2024-12-07T19:54:34+00:00 weekly 0.7 https://trial.medpath.com/news/commands-trial-shows-impact-of-luspatercept-on-rbc-transfusion-burden-in-lr-mds 2024-12-07T19:38:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/commands-trial-shows-impact-of-luspatercept-on-rbc-transfusion-burden-in-lr-mds 2024-12-07T19:38:32+00:00 weekly 0.7 https://trial.medpath.com/news/reliev2-cm-study-launched-dose-finding-portion-of-anqur-underway-anavex-submits 2024-12-07T18:14:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/reliev2-cm-study-launched-dose-finding-portion-of-anqur-underway-anavex-submits 2024-12-07T18:14:07+00:00 weekly 0.7 https://trial.medpath.com/news/sickle-cell-breakthrough-base-editing-success-mirage-news 2024-12-07T17:53:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sickle-cell-breakthrough-base-editing-success-mirage-news 2024-12-07T17:53:03+00:00 weekly 0.7 https://trial.medpath.com/news/updated-results-of-phase-3-allele-study-presented-at-66th-american-society-of-pr-newswire 2024-12-07T17:45:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/updated-results-of-phase-3-allele-study-presented-at-66th-american-society-of-pr-newswire 2024-12-07T17:45:34+00:00 weekly 0.7 https://trial.medpath.com/news/latest-advances-in-aml-treatment-highlighted-at-ash-2024-annual-meeting 2024-12-07T17:43:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/latest-advances-in-aml-treatment-highlighted-at-ash-2024-annual-meeting 2024-12-07T17:43:00+00:00 weekly 0.7 https://trial.medpath.com/news/talazoparib-plus-enzalutamide-versus-olaparib-plus-abiraterone-acetate-and-niraparib-nature 2024-12-07T17:38:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/talazoparib-plus-enzalutamide-versus-olaparib-plus-abiraterone-acetate-and-niraparib-nature 2024-12-07T17:38:01+00:00 weekly 0.7 https://trial.medpath.com/news/roswell-park-study-reveals-how-venetoclax-boosts-immune-response-to-car-t-for 2024-12-07T17:33:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roswell-park-study-reveals-how-venetoclax-boosts-immune-response-to-car-t-for 2024-12-07T17:33:58+00:00 weekly 0.7 https://trial.medpath.com/news/blueprint-medicines-continued-leadership-in-redefining-the-standard-of-care-in-systemic 2024-12-07T17:33:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/blueprint-medicines-continued-leadership-in-redefining-the-standard-of-care-in-systemic 2024-12-07T17:33:09+00:00 weekly 0.7 https://trial.medpath.com/news/valley-doctor-receives-grant-to-help-fight-pediatric-cancer-abc30-fresno 2024-12-07T17:15:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/valley-doctor-receives-grant-to-help-fight-pediatric-cancer-abc30-fresno 2024-12-07T17:15:34+00:00 weekly 0.7 https://trial.medpath.com/news/nektar-s-nktr-255-achieves-breakthrough-73-response-rate-in-lymphoma-trial 2024-12-07T17:15:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nektar-s-nktr-255-achieves-breakthrough-73-response-rate-in-lymphoma-trial 2024-12-07T17:15:02+00:00 weekly 0.7 https://trial.medpath.com/news/eltrombopag-improves-outcomes-in-kids-with-newly-diagnosed-itp-medpage-today 2024-12-07T17:00:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eltrombopag-improves-outcomes-in-kids-with-newly-diagnosed-itp-medpage-today 2024-12-07T17:00:07+00:00 weekly 0.7 https://trial.medpath.com/news/phase-2-data-from-the-ongoing-hibiscus-study-shows-promise-that-investigational-morningstar 2024-12-07T16:55:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-2-data-from-the-ongoing-hibiscus-study-shows-promise-that-investigational-morningstar 2024-12-07T16:55:48+00:00 weekly 0.7 https://trial.medpath.com/news/beam-therapeutics-announces-new-data-from-beacon-phase-1-2-clinical-trial-yahoo-finance 2024-12-07T16:47:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/beam-therapeutics-announces-new-data-from-beacon-phase-1-2-clinical-trial-yahoo-finance 2024-12-07T16:47:04+00:00 weekly 0.7 https://trial.medpath.com/news/bioage-shares-tumble-after-decision-to-halt-obesity-drug-study-biopharma-dive 2024-12-07T16:37:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bioage-shares-tumble-after-decision-to-halt-obesity-drug-study-biopharma-dive 2024-12-07T16:37:40+00:00 weekly 0.7 https://trial.medpath.com/news/the-latest-progress-in-the-application-of-telitacicept-in-autoimmune-diseases 2024-12-07T16:37:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-latest-progress-in-the-application-of-telitacicept-in-autoimmune-diseases 2024-12-07T16:37:12+00:00 weekly 0.7 https://trial.medpath.com/news/press-release-ash-rilzabrutinib-demonstrated-significant-globenewswire 2024-12-07T16:32:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/press-release-ash-rilzabrutinib-demonstrated-significant-globenewswire 2024-12-07T16:32:37+00:00 weekly 0.7 https://trial.medpath.com/news/global-clinical-trial-shows-improved-survival-rates-for-common-childhood-leukemia 2024-12-07T15:09:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-clinical-trial-shows-improved-survival-rates-for-common-childhood-leukemia 2024-12-07T15:09:13+00:00 weekly 0.7 https://trial.medpath.com/news/dual-targeted-car-t-yields-99-response-rate-in-pediatric-all-medpage-today 2024-12-07T15:01:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dual-targeted-car-t-yields-99-response-rate-in-pediatric-all-medpage-today 2024-12-07T15:01:21+00:00 weekly 0.7 https://trial.medpath.com/news/cdsco-waives-local-clinical-trials-for-new-drugs-approved-in-the-us-the-hindu 2024-12-07T14:58:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cdsco-waives-local-clinical-trials-for-new-drugs-approved-in-the-us-the-hindu 2024-12-07T14:58:56+00:00 weekly 0.7 https://trial.medpath.com/news/iit-r-researchers-claim-key-insights-in-antibiotic-resistance-mechanisms-in-bacteria 2024-12-07T14:58:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iit-r-researchers-claim-key-insights-in-antibiotic-resistance-mechanisms-in-bacteria 2024-12-07T14:58:18+00:00 weekly 0.7 https://trial.medpath.com/news/bioage-labs-announces-discontinuation-of-strides-phase-2-globenewswire 2024-12-07T14:50:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bioage-labs-announces-discontinuation-of-strides-phase-2-globenewswire 2024-12-07T14:50:52+00:00 weekly 0.7 https://trial.medpath.com/news/india-s-eco-system-for-onco-clinical-trials-will-accelerate-best-in-class-drugs-for-patients 2024-12-07T14:31:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/india-s-eco-system-for-onco-clinical-trials-will-accelerate-best-in-class-drugs-for-patients 2024-12-07T14:31:10+00:00 weekly 0.7 https://trial.medpath.com/news/top-5-infectious-disease-news-stories-week-of-november-30-december-6-contagion-live 2024-12-07T14:10:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-5-infectious-disease-news-stories-week-of-november-30-december-6-contagion-live 2024-12-07T14:10:08+00:00 weekly 0.7 https://trial.medpath.com/news/ash-2024-expert-highlights-zanubrutinib-s-sustained-efficacy-favorable-safety-profile-in-cll 2024-12-07T14:06:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ash-2024-expert-highlights-zanubrutinib-s-sustained-efficacy-favorable-safety-profile-in-cll 2024-12-07T14:06:04+00:00 weekly 0.7 https://trial.medpath.com/news/fda-must-disclose-more-covid-19-vaccine-records-us-judge-rules-et-healthworld 2024-12-07T13:27:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-must-disclose-more-covid-19-vaccine-records-us-judge-rules-et-healthworld 2024-12-07T13:27:19+00:00 weekly 0.7 https://trial.medpath.com/news/ratner-honored-for-career-contributions-to-nf1-research 2024-12-07T13:04:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ratner-honored-for-career-contributions-to-nf1-research 2024-12-07T13:04:27+00:00 weekly 0.7 https://trial.medpath.com/news/incyte-announces-positive-results-from-phase-3-trial-evaluating-retifanlimab-zynyz-r-in 2024-12-07T12:34:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/incyte-announces-positive-results-from-phase-3-trial-evaluating-retifanlimab-zynyz-r-in 2024-12-07T12:34:23+00:00 weekly 0.7 https://trial.medpath.com/news/similar-persistence-rates-between-adalimumab-new-starts-switched-patients 2024-12-07T12:03:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/similar-persistence-rates-between-adalimumab-new-starts-switched-patients 2024-12-07T12:03:23+00:00 weekly 0.7 https://trial.medpath.com/news/curis-to-report-third-quarter-2024-financial-and-operating-results-and-host-conference 2024-12-07T11:57:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/curis-to-report-third-quarter-2024-financial-and-operating-results-and-host-conference 2024-12-07T11:57:31+00:00 weekly 0.7 https://trial.medpath.com/news/suo-2024-game-changing-team-science-urotoday 2024-12-07T11:47:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/suo-2024-game-changing-team-science-urotoday 2024-12-07T11:47:15+00:00 weekly 0.7 https://trial.medpath.com/news/going-boldly-first-person-treated-in-phase-1-clinical-trial-by-alnylam-pharmaceuticals 2024-12-07T11:35:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/going-boldly-first-person-treated-in-phase-1-clinical-trial-by-alnylam-pharmaceuticals 2024-12-07T11:35:09+00:00 weekly 0.7 https://trial.medpath.com/news/repurposed-drug-has-promising-efficacy-in-non-small-cell-lung-cancer 2024-12-07T11:32:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/repurposed-drug-has-promising-efficacy-in-non-small-cell-lung-cancer 2024-12-07T11:32:27+00:00 weekly 0.7 https://trial.medpath.com/news/cilcare-secures-funding-to-advance-clinical-trials-for-cochlear-synaptopathy-treatment 2024-12-07T11:23:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cilcare-secures-funding-to-advance-clinical-trials-for-cochlear-synaptopathy-treatment 2024-12-07T11:23:48+00:00 weekly 0.7 https://trial.medpath.com/news/suo-2024-exploratory-analysis-of-post-treatment-outcomes-in-patients-with-bacillus-urotoday 2024-12-07T11:06:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/suo-2024-exploratory-analysis-of-post-treatment-outcomes-in-patients-with-bacillus-urotoday 2024-12-07T11:06:47+00:00 weekly 0.7 https://trial.medpath.com/news/smoking-linked-to-increased-genetic-mutations-and-faster-disease-progression-in-myelodysplastic-syndromes 2024-12-07T10:52:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/smoking-linked-to-increased-genetic-mutations-and-faster-disease-progression-in-myelodysplastic-syndromes 2024-12-07T10:52:56+00:00 weekly 0.7 https://trial.medpath.com/news/targeting-pik3ca-with-allosteric-inhibitors-is-promising-new-approach-in-breast-cancer 2024-12-07T09:51:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/targeting-pik3ca-with-allosteric-inhibitors-is-promising-new-approach-in-breast-cancer 2024-12-07T09:51:18+00:00 weekly 0.7 https://trial.medpath.com/news/world-first-urine-test-for-lung-cancer-picks-out-zombie-cells 2024-12-07T08:16:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/world-first-urine-test-for-lung-cancer-picks-out-zombie-cells 2024-12-07T08:16:50+00:00 weekly 0.7 https://trial.medpath.com/news/ngs-and-ctdna-testing-guide-treatment-selection-and-sequencing-in-mcrc-onclive 2024-12-07T07:16:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ngs-and-ctdna-testing-guide-treatment-selection-and-sequencing-in-mcrc-onclive 2024-12-07T07:16:47+00:00 weekly 0.7 https://trial.medpath.com/news/fred-hutch-research-shines-at-national-oncology-conference 2024-12-07T06:47:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fred-hutch-research-shines-at-national-oncology-conference 2024-12-07T06:47:39+00:00 weekly 0.7 https://trial.medpath.com/news/the-launch-of-spima-therapeutics-pharmaceutical-executive 2024-12-07T06:31:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-launch-of-spima-therapeutics-pharmaceutical-executive 2024-12-07T06:31:09+00:00 weekly 0.7 https://trial.medpath.com/news/interim-analysis-highlights-long-term-safety-of-azetukalner-for-focal-epilepsy 2024-12-07T06:07:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/interim-analysis-highlights-long-term-safety-of-azetukalner-for-focal-epilepsy 2024-12-07T06:07:35+00:00 weekly 0.7 https://trial.medpath.com/news/suo-2024-co-formulated-vibostolimab-pembrolizumab-or-co-formulated-favezelimab 2024-12-07T06:06:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/suo-2024-co-formulated-vibostolimab-pembrolizumab-or-co-formulated-favezelimab 2024-12-07T06:06:42+00:00 weekly 0.7 https://trial.medpath.com/news/suo-2024-a-phase-i-dose-escalation-study-of-ugn-301-zalifrelimab-as-urotoday 2024-12-07T05:45:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/suo-2024-a-phase-i-dose-escalation-study-of-ugn-301-zalifrelimab-as-urotoday 2024-12-07T05:45:57+00:00 weekly 0.7 https://trial.medpath.com/news/ethical-considerations-for-fda-accelerated-approval-the-regulatory-review 2024-12-07T05:34:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ethical-considerations-for-fda-accelerated-approval-the-regulatory-review 2024-12-07T05:34:27+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-daiichi-build-cancer-drug-case-amgen-invests-1b-biopharma-dive 2024-12-07T04:15:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-daiichi-build-cancer-drug-case-amgen-invests-1b-biopharma-dive 2024-12-07T04:15:02+00:00 weekly 0.7 https://trial.medpath.com/news/long-term-data-on-olanzapine-and-samidorphan-highlight-maintained-schizophrenia 2024-12-07T01:50:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/long-term-data-on-olanzapine-and-samidorphan-highlight-maintained-schizophrenia 2024-12-07T01:50:55+00:00 weekly 0.7 https://trial.medpath.com/news/protara-cg-oncology-tout-promising-bladder-cancer-outcomes-biospace 2024-12-07T00:46:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/protara-cg-oncology-tout-promising-bladder-cancer-outcomes-biospace 2024-12-07T00:46:24+00:00 weekly 0.7 https://trial.medpath.com/news/ucsf-health-experts-spotlight-advances-at-hematology-conference-uc-san-francisco 2024-12-07T00:02:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ucsf-health-experts-spotlight-advances-at-hematology-conference-uc-san-francisco 2024-12-07T00:02:18+00:00 weekly 0.7 https://trial.medpath.com/news/phase-2-study-shows-promise-for-zanubrutinib-and-venetoclax-combination-in-r-r-cll 2024-12-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-2-study-shows-promise-for-zanubrutinib-and-venetoclax-combination-in-r-r-cll 2024-12-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/feasibility-of-simon-2-stage-futility-trials-in-early-parkinson-disease-pubmed 2024-12-06T23:56:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/feasibility-of-simon-2-stage-futility-trials-in-early-parkinson-disease-pubmed 2024-12-06T23:56:09+00:00 weekly 0.7 https://trial.medpath.com/news/suo-2024-mk-5684-003-a-phase-3-study-of-cyp11a1-inhibitor-opevesostat-versus-next 2024-12-06T22:24:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/suo-2024-mk-5684-003-a-phase-3-study-of-cyp11a1-inhibitor-opevesostat-versus-next 2024-12-06T22:24:30+00:00 weekly 0.7 https://trial.medpath.com/news/confirmatory-trials-us-fda-toughens-stance-on-need-for-advance-planning-due-diligence 2024-12-06T22:22:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/confirmatory-trials-us-fda-toughens-stance-on-need-for-advance-planning-due-diligence 2024-12-06T22:22:52+00:00 weekly 0.7 https://trial.medpath.com/news/phase-ii-trial-shows-decreased-lung-volume-in-nsclc-heightens-pneumonitis-risk 2024-12-06T22:16:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-ii-trial-shows-decreased-lung-volume-in-nsclc-heightens-pneumonitis-risk 2024-12-06T22:16:50+00:00 weekly 0.7 https://trial.medpath.com/news/dr-stearns-on-the-role-of-carboplatin-in-early-stage-tnbc-onclive 2024-12-06T22:16:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-stearns-on-the-role-of-carboplatin-in-early-stage-tnbc-onclive 2024-12-06T22:16:41+00:00 weekly 0.7 https://trial.medpath.com/news/dr-liu-on-the-trust-ii-trial-of-taletrectinib-in-ros1-nsclc-onclive 2024-12-06T22:16:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-liu-on-the-trust-ii-trial-of-taletrectinib-in-ros1-nsclc-onclive 2024-12-06T22:16:41+00:00 weekly 0.7 https://trial.medpath.com/news/enanta-pharma-to-unveil-breakthrough-rsv-pediatric-trial-results-key-phase-2-data-coming 2024-12-06T22:13:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enanta-pharma-to-unveil-breakthrough-rsv-pediatric-trial-results-key-phase-2-data-coming 2024-12-06T22:13:10+00:00 weekly 0.7 https://trial.medpath.com/news/drs-baljevic-and-cortes-preview-upcoming-studies-and-emerging-data-from-ash-2024 2024-12-06T22:12:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/drs-baljevic-and-cortes-preview-upcoming-studies-and-emerging-data-from-ash-2024 2024-12-06T22:12:26+00:00 weekly 0.7 https://trial.medpath.com/news/suo-2024-clinical-progression-of-prostate-cancer-from-active-surveillance-is-predicted-by 2024-12-06T21:51:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/suo-2024-clinical-progression-of-prostate-cancer-from-active-surveillance-is-predicted-by 2024-12-06T21:51:29+00:00 weekly 0.7 https://trial.medpath.com/news/patent-highlights-usp19-inhibitors-kcc2-potentiators-nrf2-inhibitors-additional-polth-inhibitors-and-more 2024-12-06T21:38:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/patent-highlights-usp19-inhibitors-kcc2-potentiators-nrf2-inhibitors-additional-polth-inhibitors-and-more 2024-12-06T21:38:51+00:00 weekly 0.7 https://trial.medpath.com/news/iron-deficiency-anemia-therapeutics-market-size-in-the-7mm-was-around-the-globe-and-mail 2024-12-06T21:10:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iron-deficiency-anemia-therapeutics-market-size-in-the-7mm-was-around-the-globe-and-mail 2024-12-06T21:10:39+00:00 weekly 0.7 https://trial.medpath.com/news/phase-one-trial-explores-novel-immunotherapy-for-breast-cancer-news-medical 2024-12-06T21:02:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-one-trial-explores-novel-immunotherapy-for-breast-cancer-news-medical 2024-12-06T21:02:56+00:00 weekly 0.7 https://trial.medpath.com/news/sana-biotechnology-stock-hits-52-week-low-at-2-29-investing-com 2024-12-06T20:57:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sana-biotechnology-stock-hits-52-week-low-at-2-29-investing-com 2024-12-06T20:57:09+00:00 weekly 0.7 https://trial.medpath.com/news/syntheticmr-receives-fda-510-k-clearance-for-symri-15-pr-newswire 2024-12-06T20:55:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/syntheticmr-receives-fda-510-k-clearance-for-symri-15-pr-newswire 2024-12-06T20:55:47+00:00 weekly 0.7 https://trial.medpath.com/news/ajmc-r-in-the-press-december-6-2024 2024-12-06T20:54:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ajmc-r-in-the-press-december-6-2024 2024-12-06T20:54:50+00:00 weekly 0.7 https://trial.medpath.com/news/fda-roundup-december-6-2024-longview-news-journal 2024-12-06T20:42:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-roundup-december-6-2024-longview-news-journal 2024-12-06T20:42:02+00:00 weekly 0.7 https://trial.medpath.com/news/ucb-eyes-two-more-approvals-after-this-year-s-success-hiteunyuseu 2024-12-06T20:17:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ucb-eyes-two-more-approvals-after-this-year-s-success-hiteunyuseu 2024-12-06T20:17:35+00:00 weekly 0.7 https://trial.medpath.com/news/duality-biologics-and-biontech-presented-positive-interim-data-for-investigational-b7-h3 2024-12-06T19:57:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/duality-biologics-and-biontech-presented-positive-interim-data-for-investigational-b7-h3 2024-12-06T19:57:31+00:00 weekly 0.7 https://trial.medpath.com/news/can-immunotherapy-go-the-distance-in-es-ls-small-cell-lung-cancer-medpage-today 2024-12-06T19:05:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/can-immunotherapy-go-the-distance-in-es-ls-small-cell-lung-cancer-medpage-today 2024-12-06T19:05:39+00:00 weekly 0.7 https://trial.medpath.com/news/community-cancer-centers-face-implementation-hurdles-with-bispecific-antibody-therapies 2024-12-06T19:02:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/community-cancer-centers-face-implementation-hurdles-with-bispecific-antibody-therapies 2024-12-06T19:02:51+00:00 weekly 0.7 https://trial.medpath.com/news/pivot-006-phase-iii-trial-of-creto-vs-surveillance-in-intermediate-risk-bladder-cancer-mark-tyson 2024-12-06T19:01:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pivot-006-phase-iii-trial-of-creto-vs-surveillance-in-intermediate-risk-bladder-cancer-mark-tyson 2024-12-06T19:01:19+00:00 weekly 0.7 https://trial.medpath.com/news/biohaven-s-novel-epilepsy-drug-shows-breakthrough-safety-profile-in-clinical-trials 2024-12-06T17:57:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biohaven-s-novel-epilepsy-drug-shows-breakthrough-safety-profile-in-clinical-trials 2024-12-06T17:57:33+00:00 weekly 0.7 https://trial.medpath.com/news/vision-rehabilitation-research-the-reporter-uab 2024-12-06T17:52:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vision-rehabilitation-research-the-reporter-uab 2024-12-06T17:52:36+00:00 weekly 0.7 https://trial.medpath.com/news/new-data-supporting-a-new-precision-medicine-approach-for-als-patients-with-geneuro-s 2024-12-06T17:43:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-data-supporting-a-new-precision-medicine-approach-for-als-patients-with-geneuro-s 2024-12-06T17:43:26+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-clinical-study-proves-traya-customized-regimen-delivers-3-times-better-results 2024-12-06T17:31:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-clinical-study-proves-traya-customized-regimen-delivers-3-times-better-results 2024-12-06T17:31:44+00:00 weekly 0.7 https://trial.medpath.com/news/copan-diagnostics-announces-fda-clearance-for-innovative-urine-collection-device 2024-12-06T17:28:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/copan-diagnostics-announces-fda-clearance-for-innovative-urine-collection-device 2024-12-06T17:28:04+00:00 weekly 0.7 https://trial.medpath.com/news/jak-inhibitor-comes-up-short-in-phase-iii-crohn-s-disease-trial-medpage-today 2024-12-06T17:25:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jak-inhibitor-comes-up-short-in-phase-iii-crohn-s-disease-trial-medpage-today 2024-12-06T17:25:20+00:00 weekly 0.7 https://trial.medpath.com/news/identifying-a-clinical-stage-small-molecule-yap-taz-tead-ppi-inhibitor-from-a-natural-yap-o-loop-peptide 2024-12-06T17:14:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/identifying-a-clinical-stage-small-molecule-yap-taz-tead-ppi-inhibitor-from-a-natural-yap-o-loop-peptide 2024-12-06T17:14:58+00:00 weekly 0.7 https://trial.medpath.com/news/phase-4-epicom-study-highlights-potential-of-cbd-in-neuropsychiatric-disorders-of 2024-12-06T17:02:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-4-epicom-study-highlights-potential-of-cbd-in-neuropsychiatric-disorders-of 2024-12-06T17:02:13+00:00 weekly 0.7 https://trial.medpath.com/news/fostamatinib-fails-to-improve-outcomes-in-hypoxemic-covid-patients-medpage-today 2024-12-06T16:36:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fostamatinib-fails-to-improve-outcomes-in-hypoxemic-covid-patients-medpage-today 2024-12-06T16:36:48+00:00 weekly 0.7 https://trial.medpath.com/news/bioarctic-doses-first-subject-in-parkinson-s-disease-therapy-trial 2024-12-06T16:01:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bioarctic-doses-first-subject-in-parkinson-s-disease-therapy-trial 2024-12-06T16:01:12+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-in-breast-cancer-progression-drug-resistance-mirage-news 2024-12-06T15:59:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-in-breast-cancer-progression-drug-resistance-mirage-news 2024-12-06T15:59:52+00:00 weekly 0.7 https://trial.medpath.com/news/indapta-therapeutics-announces-clinical-study-collaboration-with-sanofi-on-multiple 2024-12-06T15:50:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/indapta-therapeutics-announces-clinical-study-collaboration-with-sanofi-on-multiple 2024-12-06T15:50:07+00:00 weekly 0.7 https://trial.medpath.com/news/atlas-closes-450m-biotech-fund-and-other-financing-news-pharmaphorum 2024-12-06T15:43:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/atlas-closes-450m-biotech-fund-and-other-financing-news-pharmaphorum 2024-12-06T15:43:09+00:00 weekly 0.7 https://trial.medpath.com/news/ovarian-cancer-imaging-approach-could-enable-personalized-treatment-almost-immediately 2024-12-06T15:34:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ovarian-cancer-imaging-approach-could-enable-personalized-treatment-almost-immediately 2024-12-06T15:34:05+00:00 weekly 0.7 https://trial.medpath.com/news/chronic-pseudomonas-aeruginosa-pulmonary-infections-pipeline-insight-2024-globenewswire 2024-12-06T15:14:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chronic-pseudomonas-aeruginosa-pulmonary-infections-pipeline-insight-2024-globenewswire 2024-12-06T15:14:57+00:00 weekly 0.7 https://trial.medpath.com/news/steps-taken-by-the-government-to-promote-research-development-and-deployment-of-car-pib 2024-12-06T14:35:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/steps-taken-by-the-government-to-promote-research-development-and-deployment-of-car-pib 2024-12-06T14:35:25+00:00 weekly 0.7 https://trial.medpath.com/news/updated-recommendation-for-universal-hepatitis-b-vaccination-in-adults-aged-19-59-years-cdc 2024-12-06T14:11:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/updated-recommendation-for-universal-hepatitis-b-vaccination-in-adults-aged-19-59-years-cdc 2024-12-06T14:11:52+00:00 weekly 0.7 https://trial.medpath.com/news/jaguar-health-launches-major-clinical-trial-for-orphan-drug-crofelemer-in-short-bowel-syndrome 2024-12-06T13:55:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jaguar-health-launches-major-clinical-trial-for-orphan-drug-crofelemer-in-short-bowel-syndrome 2024-12-06T13:55:35+00:00 weekly 0.7 https://trial.medpath.com/news/opioids-interfere-with-cancer-immunotherapy-but-these-drugs-could-help 2024-12-06T13:28:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/opioids-interfere-with-cancer-immunotherapy-but-these-drugs-could-help 2024-12-06T13:28:56+00:00 weekly 0.7 https://trial.medpath.com/news/verrica-s-partner-files-nda-in-japan-for-breakthrough-molluscum-treatment-stock-titan 2024-12-06T13:15:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/verrica-s-partner-files-nda-in-japan-for-breakthrough-molluscum-treatment-stock-titan 2024-12-06T13:15:41+00:00 weekly 0.7 https://trial.medpath.com/news/fluorescent-imaging-technology-expedites-thoracic-surgery-in-lung-cancer 2024-12-06T13:05:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fluorescent-imaging-technology-expedites-thoracic-surgery-in-lung-cancer 2024-12-06T13:05:27+00:00 weekly 0.7 https://trial.medpath.com/news/opus-genetics-inc-to-share-6-month-efficacy-and-safety-data-on-opgx-lca5 2024-12-06T12:51:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/opus-genetics-inc-to-share-6-month-efficacy-and-safety-data-on-opgx-lca5 2024-12-06T12:51:06+00:00 weekly 0.7 https://trial.medpath.com/news/adc-therapeutics-to-provide-initial-data-update-on-lotis-7-clinical-trial-yahoo-finance 2024-12-06T12:42:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adc-therapeutics-to-provide-initial-data-update-on-lotis-7-clinical-trial-yahoo-finance 2024-12-06T12:42:52+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-novel-gene-therapy-for-fabry-disease 2024-12-06T11:48:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-novel-gene-therapy-for-fabry-disease 2024-12-06T11:48:38+00:00 weekly 0.7 https://trial.medpath.com/news/centerline-biomedical-receives-us-fda-510-k-clearance-for-its-new-iops-guidewire 2024-12-06T11:31:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/centerline-biomedical-receives-us-fda-510-k-clearance-for-its-new-iops-guidewire 2024-12-06T11:31:51+00:00 weekly 0.7 https://trial.medpath.com/news/new-therapy-helps-patients-with-tough-to-treat-bladder-cancers 2024-12-06T11:12:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-therapy-helps-patients-with-tough-to-treat-bladder-cancers 2024-12-06T11:12:30+00:00 weekly 0.7 https://trial.medpath.com/news/bostonsight-publishes-pilot-study-on-prose-scleral-lenses-as-a-drug-delivery-system-for 2024-12-06T11:06:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bostonsight-publishes-pilot-study-on-prose-scleral-lenses-as-a-drug-delivery-system-for 2024-12-06T11:06:50+00:00 weekly 0.7 https://trial.medpath.com/news/summary-report-on-authorisation-tegsedi-r-swissmedic 2024-12-06T10:28:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/summary-report-on-authorisation-tegsedi-r-swissmedic 2024-12-06T10:28:41+00:00 weekly 0.7 https://trial.medpath.com/news/summary-report-on-authorisation-qdenga-r-swissmedic 2024-12-06T10:28:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/summary-report-on-authorisation-qdenga-r-swissmedic 2024-12-06T10:28:25+00:00 weekly 0.7 https://trial.medpath.com/news/hiv-aids-awareness-month-2024-looking-back-at-progress-in-gene-therapy-and-gene-editing 2024-12-06T09:17:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hiv-aids-awareness-month-2024-looking-back-at-progress-in-gene-therapy-and-gene-editing 2024-12-06T09:17:35+00:00 weekly 0.7 https://trial.medpath.com/news/galimedix-therapeutics-initiates-phase-1-trial-of-oral-gal-101 2024-12-06T09:11:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/galimedix-therapeutics-initiates-phase-1-trial-of-oral-gal-101 2024-12-06T09:11:44+00:00 weekly 0.7 https://trial.medpath.com/news/florida-cancer-specialists-research-institute-building-knowledge-and-improving-pr-newswire 2024-12-06T08:48:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/florida-cancer-specialists-research-institute-building-knowledge-and-improving-pr-newswire 2024-12-06T08:48:10+00:00 weekly 0.7 https://trial.medpath.com/news/ai-adoption-in-pharma-r-d-reaches-49-icon-survey-reveals-growing-industry-confidence 2024-12-06T08:10:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-adoption-in-pharma-r-d-reaches-49-icon-survey-reveals-growing-industry-confidence 2024-12-06T08:10:44+00:00 weekly 0.7 https://trial.medpath.com/news/finding-hope-with-antibody-drug-conjugates-in-managing-breast-cancer-cure-today 2024-12-06T08:04:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/finding-hope-with-antibody-drug-conjugates-in-managing-breast-cancer-cure-today 2024-12-06T08:04:07+00:00 weekly 0.7 https://trial.medpath.com/news/ugn-102-showed-promising-long-term-results-in-the-phase-3-envision-trial-potentially 2024-12-06T07:25:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ugn-102-showed-promising-long-term-results-in-the-phase-3-envision-trial-potentially 2024-12-06T07:25:48+00:00 weekly 0.7 https://trial.medpath.com/news/suo-2024-trial-design-for-bcg-unresponsive-nmibc-time-to-move-past-single-arm 2024-12-06T06:55:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/suo-2024-trial-design-for-bcg-unresponsive-nmibc-time-to-move-past-single-arm 2024-12-06T06:55:14+00:00 weekly 0.7 https://trial.medpath.com/news/innate-pharma-secures-7-9m-partnership-deal-for-lymphoma-drug-development 2024-12-06T06:48:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innate-pharma-secures-7-9m-partnership-deal-for-lymphoma-drug-development 2024-12-06T06:48:06+00:00 weekly 0.7 https://trial.medpath.com/news/dbv-upbeat-on-allergy-patch-studies-approval-chances-allergic-living 2024-12-06T06:39:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dbv-upbeat-on-allergy-patch-studies-approval-chances-allergic-living 2024-12-06T06:39:24+00:00 weekly 0.7 https://trial.medpath.com/news/new-phase-iiib-data-shows-novartis-fabhalta-r-improved-globenewswire 2024-12-06T06:17:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-phase-iiib-data-shows-novartis-fabhalta-r-improved-globenewswire 2024-12-06T06:17:00+00:00 weekly 0.7 https://trial.medpath.com/news/diversity-equity-and-inclusion-guidelines-still-not-optimal-for-hiv-positive-patients 2024-12-06T06:00:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diversity-equity-and-inclusion-guidelines-still-not-optimal-for-hiv-positive-patients 2024-12-06T06:00:01+00:00 weekly 0.7 https://trial.medpath.com/news/sulthiame-shows-promise-in-treating-obstructive-sleep-apnea-leads-ers-congress-2024-highlights 2024-12-06T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sulthiame-shows-promise-in-treating-obstructive-sleep-apnea-leads-ers-congress-2024-highlights 2024-12-06T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/is-it-time-to-approve-drugs-based-on-amyloid-removal-alzforum 2024-12-06T05:08:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/is-it-time-to-approve-drugs-based-on-amyloid-removal-alzforum 2024-12-06T05:08:30+00:00 weekly 0.7 https://trial.medpath.com/news/addition-of-cadonilimab-improves-survival-in-advanced-cervical-cancer-oncology-nursing-news 2024-12-06T05:06:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/addition-of-cadonilimab-improves-survival-in-advanced-cervical-cancer-oncology-nursing-news 2024-12-06T05:06:08+00:00 weekly 0.7 https://trial.medpath.com/news/fda-releases-draft-on-accelerated-approvals-for-drugs-biologics-bloomberg-law-news 2024-12-06T04:37:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-releases-draft-on-accelerated-approvals-for-drugs-biologics-bloomberg-law-news 2024-12-06T04:37:21+00:00 weekly 0.7 https://trial.medpath.com/news/pharmac-funds-new-cancer-rsv-copd-treatments-rnz-news 2024-12-06T04:36:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharmac-funds-new-cancer-rsv-copd-treatments-rnz-news 2024-12-06T04:36:38+00:00 weekly 0.7 https://trial.medpath.com/news/tpf-participation-department-of-transportation-commonwealth-of-pennsylvania 2024-12-06T04:36:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tpf-participation-department-of-transportation-commonwealth-of-pennsylvania 2024-12-06T04:36:23+00:00 weekly 0.7 https://trial.medpath.com/news/technology-revolutionizes-patient-registries-enhanced-real-world-evidence-collection-through-digital-innovation 2024-12-06T03:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/technology-revolutionizes-patient-registries-enhanced-real-world-evidence-collection-through-digital-innovation 2024-12-06T03:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/comparing-models-that-integrate-obstetric-care-and-wic-on-improved-program-enrollment 2024-12-06T03:13:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/comparing-models-that-integrate-obstetric-care-and-wic-on-improved-program-enrollment 2024-12-06T03:13:54+00:00 weekly 0.7 https://trial.medpath.com/news/nuvalent-s-swot-analysis-promising-pipeline-drives-stock-outlook-investing-com 2024-12-06T03:00:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nuvalent-s-swot-analysis-promising-pipeline-drives-stock-outlook-investing-com 2024-12-06T03:00:22+00:00 weekly 0.7 https://trial.medpath.com/news/studies-show-more-promising-results-for-rsv-drug-nirsevimab-cidrap 2024-12-06T03:00:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/studies-show-more-promising-results-for-rsv-drug-nirsevimab-cidrap 2024-12-06T03:00:18+00:00 weekly 0.7 https://trial.medpath.com/news/major-treg-summit-to-showcase-latest-advances-in-autoimmune-disease-treatment-development 2024-12-06T02:36:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/major-treg-summit-to-showcase-latest-advances-in-autoimmune-disease-treatment-development 2024-12-06T02:36:46+00:00 weekly 0.7 https://trial.medpath.com/news/suo-2024-strategies-for-rplnd-in-metastatic-testicular-seminoma-urotoday 2024-12-06T01:09:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/suo-2024-strategies-for-rplnd-in-metastatic-testicular-seminoma-urotoday 2024-12-06T01:09:40+00:00 weekly 0.7 https://trial.medpath.com/news/affimed-announces-acimtamig-and-allonk-r-combination-granted-globenewswire 2024-12-05T23:31:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/affimed-announces-acimtamig-and-allonk-r-combination-granted-globenewswire 2024-12-05T23:31:46+00:00 weekly 0.7 https://trial.medpath.com/news/medicinova-presents-study-update-and-interim-analysis-of-phase-2-3-clinical-trial-of-mn 2024-12-05T23:12:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medicinova-presents-study-update-and-interim-analysis-of-phase-2-3-clinical-trial-of-mn 2024-12-05T23:12:16+00:00 weekly 0.7 https://trial.medpath.com/news/kalvista-pharmaceuticals-inc-sec-10-q-report-tradingview 2024-12-05T22:36:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kalvista-pharmaceuticals-inc-sec-10-q-report-tradingview 2024-12-05T22:36:47+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-ns-050-ncnp-03-rare-pediatric-disease-designation-in-duchenne-muscular-dystrophy 2024-12-05T22:07:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-ns-050-ncnp-03-rare-pediatric-disease-designation-in-duchenne-muscular-dystrophy 2024-12-05T22:07:08+00:00 weekly 0.7 https://trial.medpath.com/news/suo-2024-sunrise-5-a-phase-iii-randomized-open-label-study-of-tar-200-compared 2024-12-05T22:05:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/suo-2024-sunrise-5-a-phase-iii-randomized-open-label-study-of-tar-200-compared 2024-12-05T22:05:40+00:00 weekly 0.7 https://trial.medpath.com/news/brief-everest-unveils-positive-results-for-kidney-drug-ever001-in-phase-1b-2a-trial 2024-12-05T21:38:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/brief-everest-unveils-positive-results-for-kidney-drug-ever001-in-phase-1b-2a-trial 2024-12-05T21:38:27+00:00 weekly 0.7 https://trial.medpath.com/news/bcm-receives-3-5-million-to-study-telehealth-genetic-services-for-sick-underserved-newborns 2024-12-05T21:09:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bcm-receives-3-5-million-to-study-telehealth-genetic-services-for-sick-underserved-newborns 2024-12-05T21:09:28+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-formulation-of-pazopanib-tablets-in-rcc-sarcoma-cancer-network 2024-12-05T20:25:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-new-formulation-of-pazopanib-tablets-in-rcc-sarcoma-cancer-network 2024-12-05T20:25:26+00:00 weekly 0.7 https://trial.medpath.com/news/how-the-healy-als-platform-trial-is-helping-to-accelerate-the-pathway-to-new-als-treatments 2024-12-05T20:22:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/how-the-healy-als-platform-trial-is-helping-to-accelerate-the-pathway-to-new-als-treatments 2024-12-05T20:22:39+00:00 weekly 0.7 https://trial.medpath.com/news/research-roundup-the-latest-science-discoveries-and-breakthroughs 2024-12-05T20:04:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/research-roundup-the-latest-science-discoveries-and-breakthroughs 2024-12-05T20:04:16+00:00 weekly 0.7 https://trial.medpath.com/news/lungpacer-medical-announces-premarket-approval-for-aeropace-r-system-biospace 2024-12-05T19:53:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lungpacer-medical-announces-premarket-approval-for-aeropace-r-system-biospace 2024-12-05T19:53:23+00:00 weekly 0.7 https://trial.medpath.com/news/tilt-biotherapeutics-provides-update-on-international-clinical-trial-progress-with-biospace 2024-12-05T19:53:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tilt-biotherapeutics-provides-update-on-international-clinical-trial-progress-with-biospace 2024-12-05T19:53:14+00:00 weekly 0.7 https://trial.medpath.com/news/nuvig-pulls-in-161m-to-make-better-immune-drugs-biopharma-dive 2024-12-05T19:53:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nuvig-pulls-in-161m-to-make-better-immune-drugs-biopharma-dive 2024-12-05T19:53:13+00:00 weekly 0.7 https://trial.medpath.com/news/protera-therapeutics-stock-remains-buy-rated-after-promising-tara-002-phase-ii-results 2024-12-05T19:28:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/protera-therapeutics-stock-remains-buy-rated-after-promising-tara-002-phase-ii-results 2024-12-05T19:28:36+00:00 weekly 0.7 https://trial.medpath.com/news/rochester-regional-health-s-sands-constellation-heart-institute-becomes-first-u-s-site-for 2024-12-05T19:16:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rochester-regional-health-s-sands-constellation-heart-institute-becomes-first-u-s-site-for 2024-12-05T19:16:28+00:00 weekly 0.7 https://trial.medpath.com/news/immunotherapy-redefines-standard-of-care-for-frontline-advanced-endometrial-cancer 2024-12-05T19:05:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunotherapy-redefines-standard-of-care-for-frontline-advanced-endometrial-cancer 2024-12-05T19:05:47+00:00 weekly 0.7 https://trial.medpath.com/news/cytokine-tv-implantable-protein-sensors-monitor-live-inflammation 2024-12-05T19:02:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cytokine-tv-implantable-protein-sensors-monitor-live-inflammation 2024-12-05T19:02:53+00:00 weekly 0.7 https://trial.medpath.com/news/maat-pharma-sa-announces-first-u-s-patient-treated-at-city-of-hope-under-marketscreener 2024-12-05T19:01:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maat-pharma-sa-announces-first-u-s-patient-treated-at-city-of-hope-under-marketscreener 2024-12-05T19:01:51+00:00 weekly 0.7 https://trial.medpath.com/news/new-drug-tested-to-reduce-side-effect-of-half-matched-stem-cell-transplants 2024-12-05T18:46:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-drug-tested-to-reduce-side-effect-of-half-matched-stem-cell-transplants 2024-12-05T18:46:50+00:00 weekly 0.7 https://trial.medpath.com/news/epicentrx-s-oncolytic-virus-delivered-tgfb-inhibitor-adapt-001-receives-fda-fast-track 2024-12-05T18:45:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/epicentrx-s-oncolytic-virus-delivered-tgfb-inhibitor-adapt-001-receives-fda-fast-track 2024-12-05T18:45:59+00:00 weekly 0.7 https://trial.medpath.com/news/strong-safety-nuanced-efficacy-results-for-canakinumab-in-previously-treated-mds 2024-12-05T18:29:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/strong-safety-nuanced-efficacy-results-for-canakinumab-in-previously-treated-mds 2024-12-05T18:29:59+00:00 weekly 0.7 https://trial.medpath.com/news/long-term-efficacy-of-first-line-afatinib-and-the-clinical-utility-of-ctdna-monitoring-in-patients 2024-12-05T18:28:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/long-term-efficacy-of-first-line-afatinib-and-the-clinical-utility-of-ctdna-monitoring-in-patients 2024-12-05T18:28:37+00:00 weekly 0.7 https://trial.medpath.com/news/lundbeck-highlights-commitment-to-the-rare-epilepsy-community-at-american-cision-news 2024-12-05T18:08:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lundbeck-highlights-commitment-to-the-rare-epilepsy-community-at-american-cision-news 2024-12-05T18:08:47+00:00 weekly 0.7 https://trial.medpath.com/news/rubi-secures-1-million-phase-ii-grant-from-the-national-science-foundation-to-scale-its 2024-12-05T17:50:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rubi-secures-1-million-phase-ii-grant-from-the-national-science-foundation-to-scale-its 2024-12-05T17:50:39+00:00 weekly 0.7 https://trial.medpath.com/news/evaluation-of-a-mobile-application-to-decrease-opioid-misuse-in-patients-undergoing 2024-12-05T17:31:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evaluation-of-a-mobile-application-to-decrease-opioid-misuse-in-patients-undergoing 2024-12-05T17:31:51+00:00 weekly 0.7 https://trial.medpath.com/news/the-long-journey-of-a-small-molecule-of-hope-research-horizons 2024-12-05T17:26:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-long-journey-of-a-small-molecule-of-hope-research-horizons 2024-12-05T17:26:09+00:00 weekly 0.7 https://trial.medpath.com/news/study-finds-tonsil-removal-not-linked-to-weight-gain-contrary-to-popular-belief-michigan-medicine 2024-12-05T16:05:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-finds-tonsil-removal-not-linked-to-weight-gain-contrary-to-popular-belief-michigan-medicine 2024-12-05T16:05:12+00:00 weekly 0.7 https://trial.medpath.com/news/december-5-2024-nudge-pragmatic-trial-finds-no-improvement-in-adherence-to 2024-12-05T15:44:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/december-5-2024-nudge-pragmatic-trial-finds-no-improvement-in-adherence-to 2024-12-05T15:44:52+00:00 weekly 0.7 https://trial.medpath.com/news/simcha-therapeutics-announces-the-opening-of-two-clinical-studies-exploring-st-067-in 2024-12-05T15:31:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/simcha-therapeutics-announces-the-opening-of-two-clinical-studies-exploring-st-067-in 2024-12-05T15:31:45+00:00 weekly 0.7 https://trial.medpath.com/news/unlearn-and-apst-research-partner-to-build-high-quality-dataset-to-accelerate-als-clinical-trials 2024-12-05T15:16:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/unlearn-and-apst-research-partner-to-build-high-quality-dataset-to-accelerate-als-clinical-trials 2024-12-05T15:16:28+00:00 weekly 0.7 https://trial.medpath.com/news/suo-2024-in-depth-characterization-of-the-safety-profile-of-belzutifan-monotherapy-in-urotoday 2024-12-05T15:15:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/suo-2024-in-depth-characterization-of-the-safety-profile-of-belzutifan-monotherapy-in-urotoday 2024-12-05T15:15:16+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-eligibility-and-outcomes-in-patients-with-metastatic-nsclc-treated-outside-of 2024-12-05T15:05:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-eligibility-and-outcomes-in-patients-with-metastatic-nsclc-treated-outside-of 2024-12-05T15:05:10+00:00 weekly 0.7 https://trial.medpath.com/news/ryvu-therapeutics-announces-dosing-of-the-first-patient-in-the-potami-61-phase-ii-study 2024-12-05T14:53:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ryvu-therapeutics-announces-dosing-of-the-first-patient-in-the-potami-61-phase-ii-study 2024-12-05T14:53:26+00:00 weekly 0.7 https://trial.medpath.com/news/protara-therapeutics-inc-announces-positive-results-from-the-ongoing-phase-2-advanced 2024-12-05T14:49:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/protara-therapeutics-inc-announces-positive-results-from-the-ongoing-phase-2-advanced 2024-12-05T14:49:25+00:00 weekly 0.7 https://trial.medpath.com/news/her2-gastric-cancer-market-report-2032-epidemiology-openpr-com 2024-12-05T14:47:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/her2-gastric-cancer-market-report-2032-epidemiology-openpr-com 2024-12-05T14:47:38+00:00 weekly 0.7 https://trial.medpath.com/news/mission-bio-showcases-critical-insights-into-multiple-myeloma-aml-mrd-car-t-safety 2024-12-05T14:39:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mission-bio-showcases-critical-insights-into-multiple-myeloma-aml-mrd-car-t-safety 2024-12-05T14:39:22+00:00 weekly 0.7 https://trial.medpath.com/news/simx-receives-1-25m-phase-ii-sttr-grant-from-afwerx-to-advance-vr-training-for 2024-12-05T13:52:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/simx-receives-1-25m-phase-ii-sttr-grant-from-afwerx-to-advance-vr-training-for 2024-12-05T13:52:57+00:00 weekly 0.7 https://trial.medpath.com/news/cu-cancer-center-member-breelyn-wilky-md-oversees-trial-of-new-treatment-for-sarcomas 2024-12-05T13:36:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cu-cancer-center-member-breelyn-wilky-md-oversees-trial-of-new-treatment-for-sarcomas 2024-12-05T13:36:45+00:00 weekly 0.7 https://trial.medpath.com/news/aurobindo-pharma-wins-usfda-approval-for-generic-cancer-drug-the-hindu-businessline 2024-12-05T13:09:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aurobindo-pharma-wins-usfda-approval-for-generic-cancer-drug-the-hindu-businessline 2024-12-05T13:09:46+00:00 weekly 0.7 https://trial.medpath.com/news/suo-2024-disease-free-survival-and-overall-survival-in-patients-with-high-risk-muscle 2024-12-05T13:09:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/suo-2024-disease-free-survival-and-overall-survival-in-patients-with-high-risk-muscle 2024-12-05T13:09:17+00:00 weekly 0.7 https://trial.medpath.com/news/annexon-to-present-phase-2-archer-data-on-protection-of-globenewswire 2024-12-05T13:02:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/annexon-to-present-phase-2-archer-data-on-protection-of-globenewswire 2024-12-05T13:02:51+00:00 weekly 0.7 https://trial.medpath.com/news/theriva-biologics-gets-fda-guidance-on-vcn-01-phase-3-trial-design-for-pancreatic 2024-12-05T13:02:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/theriva-biologics-gets-fda-guidance-on-vcn-01-phase-3-trial-design-for-pancreatic 2024-12-05T13:02:05+00:00 weekly 0.7 https://trial.medpath.com/news/denali-therapeutics-launches-key-phase-2a-trial-for-breakthrough-parkinson-s-treatment 2024-12-05T13:02:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/denali-therapeutics-launches-key-phase-2a-trial-for-breakthrough-parkinson-s-treatment 2024-12-05T13:02:03+00:00 weekly 0.7 https://trial.medpath.com/news/imfinzi-approved-in-the-us-as-first-and-only-immunotherapy-regimen-for-patients-with-limited 2024-12-05T13:01:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/imfinzi-approved-in-the-us-as-first-and-only-immunotherapy-regimen-for-patients-with-limited 2024-12-05T13:01:23+00:00 weekly 0.7 https://trial.medpath.com/news/single-versus-tandem-autologous-stem-cell-transplantation-in-newly-diagnosed-multiple-myeloma 2024-12-05T12:41:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/single-versus-tandem-autologous-stem-cell-transplantation-in-newly-diagnosed-multiple-myeloma 2024-12-05T12:41:36+00:00 weekly 0.7 https://trial.medpath.com/news/theralase-r-launches-new-clinical-study-site-in-canada-corsicana-daily-sun 2024-12-05T12:22:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/theralase-r-launches-new-clinical-study-site-in-canada-corsicana-daily-sun 2024-12-05T12:22:53+00:00 weekly 0.7 https://trial.medpath.com/news/yap1-and-kras-identified-as-key-drivers-in-soft-tissue-sarcoma-development-opening-new-treatment-avenues 2024-12-05T12:19:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/yap1-and-kras-identified-as-key-drivers-in-soft-tissue-sarcoma-development-opening-new-treatment-avenues 2024-12-05T12:19:35+00:00 weekly 0.7 https://trial.medpath.com/news/the-us-fda-approves-ibox-french-algorithm-for-predicting-kidney-graft-survival 2024-12-05T12:11:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-us-fda-approves-ibox-french-algorithm-for-predicting-kidney-graft-survival 2024-12-05T12:11:47+00:00 weekly 0.7 https://trial.medpath.com/news/ntc-presents-positive-results-from-phase-ii-mirakle-study-evaluating-an-innovative-drug-for 2024-12-05T11:56:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ntc-presents-positive-results-from-phase-ii-mirakle-study-evaluating-an-innovative-drug-for 2024-12-05T11:56:19+00:00 weekly 0.7 https://trial.medpath.com/news/merck-and-ridgeback-biotherapeutics-announce-initiation-of-phase-3-study-move-now 2024-12-05T11:50:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-and-ridgeback-biotherapeutics-announce-initiation-of-phase-3-study-move-now 2024-12-05T11:50:10+00:00 weekly 0.7 https://trial.medpath.com/news/kalvista-pharmaceuticals-reports-second-fiscal-quarter-results-and-provides-operational-update 2024-12-05T11:35:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kalvista-pharmaceuticals-reports-second-fiscal-quarter-results-and-provides-operational-update 2024-12-05T11:35:35+00:00 weekly 0.7 https://trial.medpath.com/news/most-young-people-with-long-covid-recover-within-2-years 2024-12-05T11:12:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/most-young-people-with-long-covid-recover-within-2-years 2024-12-05T11:12:20+00:00 weekly 0.7 https://trial.medpath.com/news/nanox-secures-major-fda-clearance-expansion-for-revolutionary-digital-x-ray-system 2024-12-05T11:03:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nanox-secures-major-fda-clearance-expansion-for-revolutionary-digital-x-ray-system 2024-12-05T11:03:36+00:00 weekly 0.7 https://trial.medpath.com/news/media-advisory-abnormal-prenatal-blood-test-results-could-indicate-hidden-maternal-cancers 2024-12-05T10:04:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/media-advisory-abnormal-prenatal-blood-test-results-could-indicate-hidden-maternal-cancers 2024-12-05T10:04:13+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-outsourcing-market-set-to-reach-91-2-billion-by-2034-driven-by-technology-integration-and-strategic-partnerships 2024-12-05T09:31:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-outsourcing-market-set-to-reach-91-2-billion-by-2034-driven-by-technology-integration-and-strategic-partnerships 2024-12-05T09:31:39+00:00 weekly 0.7 https://trial.medpath.com/news/safety-and-effectiveness-of-transcutaneous-auricular-vagus-nerve-stimulation-on-patients 2024-12-05T09:26:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/safety-and-effectiveness-of-transcutaneous-auricular-vagus-nerve-stimulation-on-patients 2024-12-05T09:26:52+00:00 weekly 0.7 https://trial.medpath.com/news/uk-first-country-in-europe-to-reimburse-tirzepatide-european-biotechnology-magazine 2024-12-05T09:21:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uk-first-country-in-europe-to-reimburse-tirzepatide-european-biotechnology-magazine 2024-12-05T09:21:52+00:00 weekly 0.7 https://trial.medpath.com/news/who-senior-adviser-calls-for-systematic-reviews-to-address-clinical-trial-diversity-gap 2024-12-05T08:59:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/who-senior-adviser-calls-for-systematic-reviews-to-address-clinical-trial-diversity-gap 2024-12-05T08:59:25+00:00 weekly 0.7 https://trial.medpath.com/news/avistone-announces-updates-on-ans03-biospace 2024-12-05T08:25:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avistone-announces-updates-on-ans03-biospace 2024-12-05T08:25:09+00:00 weekly 0.7 https://trial.medpath.com/news/3-asx-biotech-shares-rocketing-10-to-26-on-big-news-motley-fool 2024-12-05T08:09:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/3-asx-biotech-shares-rocketing-10-to-26-on-big-news-motley-fool 2024-12-05T08:09:30+00:00 weekly 0.7 https://trial.medpath.com/news/first-cd20xcd3-antibody-shows-survival-benefits-in-phase-iii-lymphoma-trial-rhhby-stock-news 2024-12-05T08:05:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-cd20xcd3-antibody-shows-survival-benefits-in-phase-iii-lymphoma-trial-rhhby-stock-news 2024-12-05T08:05:42+00:00 weekly 0.7 https://trial.medpath.com/news/theralase-technologies-inc-tltff-q3-2024-earnings-call-highlig-gurufocus 2024-12-05T07:28:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/theralase-technologies-inc-tltff-q3-2024-earnings-call-highlig-gurufocus 2024-12-05T07:28:34+00:00 weekly 0.7 https://trial.medpath.com/news/physiomics-secures-new-contract-with-numab-therapeutics-for-inflammation-study 2024-12-05T07:14:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/physiomics-secures-new-contract-with-numab-therapeutics-for-inflammation-study 2024-12-05T07:14:01+00:00 weekly 0.7 https://trial.medpath.com/news/ips-test-shows-promise-in-guiding-immunotherapy-decisions-for-solid-tumor-treatment 2024-12-05T07:01:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ips-test-shows-promise-in-guiding-immunotherapy-decisions-for-solid-tumor-treatment 2024-12-05T07:01:43+00:00 weekly 0.7 https://trial.medpath.com/news/cyp-006tk-demonstrates-safety-and-efficacy-in-dfu-clinical-trial-biospace 2024-12-05T06:48:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cyp-006tk-demonstrates-safety-and-efficacy-in-dfu-clinical-trial-biospace 2024-12-05T06:48:02+00:00 weekly 0.7 https://trial.medpath.com/news/acrux-gains-fda-approval-and-raises-2-65-million-markets-insider 2024-12-05T06:46:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acrux-gains-fda-approval-and-raises-2-65-million-markets-insider 2024-12-05T06:46:01+00:00 weekly 0.7 https://trial.medpath.com/news/nxera-pharma-enrolls-first-insomnia-patient-in-its-phase-3-globenewswire 2024-12-05T06:07:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nxera-pharma-enrolls-first-insomnia-patient-in-its-phase-3-globenewswire 2024-12-05T06:07:20+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-advances-in-lung-cancer-treatment-combine-early-detection-and-personalized-therapies 2024-12-05T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-advances-in-lung-cancer-treatment-combine-early-detection-and-personalized-therapies 2024-12-05T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gut-microbiota-modulation-a-novel-mechanism-in-arb-mediated-hypertension-treatment 2024-12-05T05:56:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gut-microbiota-modulation-a-novel-mechanism-in-arb-mediated-hypertension-treatment 2024-12-05T05:56:08+00:00 weekly 0.7 https://trial.medpath.com/news/anatara-provides-irritable-bowel-syndrome-clinical-trial-update-biotech-dispatch 2024-12-05T05:23:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/anatara-provides-irritable-bowel-syndrome-clinical-trial-update-biotech-dispatch 2024-12-05T05:23:09+00:00 weekly 0.7 https://trial.medpath.com/news/how-bad-is-fraud-in-alzheimer-s-research-q-a-with-neurologist-sleuth-matthew-schrag 2024-12-05T05:17:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/how-bad-is-fraud-in-alzheimer-s-research-q-a-with-neurologist-sleuth-matthew-schrag 2024-12-05T05:17:26+00:00 weekly 0.7 https://trial.medpath.com/news/durvalumab-wins-fda-approval-in-limited-stage-small-cell-lung-cancer 2024-12-05T04:59:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/durvalumab-wins-fda-approval-in-limited-stage-small-cell-lung-cancer 2024-12-05T04:59:33+00:00 weekly 0.7 https://trial.medpath.com/news/edgewise-therapeutics-swot-analysis-biotech-stock-poised-for-growth-amid-clinical-milestones 2024-12-05T04:44:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/edgewise-therapeutics-swot-analysis-biotech-stock-poised-for-growth-amid-clinical-milestones 2024-12-05T04:44:11+00:00 weekly 0.7 https://trial.medpath.com/news/us-abortion-laws-could-deter-women-s-participation-in-clinical-research-raising-scientific-and-ethical-concerns 2024-12-05T04:38:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/us-abortion-laws-could-deter-women-s-participation-in-clinical-research-raising-scientific-and-ethical-concerns 2024-12-05T04:38:17+00:00 weekly 0.7 https://trial.medpath.com/news/how-cedars-sinai-increased-black-and-hispanic-clinical-trial-enrollment-blackdoctor-org 2024-12-05T04:10:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/how-cedars-sinai-increased-black-and-hispanic-clinical-trial-enrollment-blackdoctor-org 2024-12-05T04:10:59+00:00 weekly 0.7 https://trial.medpath.com/news/terns-pharmaceuticals-allosteric-inhibitor-shows-best-in-class-potential-in-phase-i-cml-study 2024-12-05T04:07:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/terns-pharmaceuticals-allosteric-inhibitor-shows-best-in-class-potential-in-phase-i-cml-study 2024-12-05T04:07:05+00:00 weekly 0.7 https://trial.medpath.com/news/tirzepatide-shows-47-greater-weight-loss-than-semaglutide-in-72-week-phase-3b-study 2024-12-05T03:54:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tirzepatide-shows-47-greater-weight-loss-than-semaglutide-in-72-week-phase-3b-study 2024-12-05T03:54:55+00:00 weekly 0.7 https://trial.medpath.com/news/appeals-court-denies-novartis-bid-to-block-generic-entresto-threatening-5-6b-revenue-stream 2024-12-05T03:14:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/appeals-court-denies-novartis-bid-to-block-generic-entresto-threatening-5-6b-revenue-stream 2024-12-05T03:14:20+00:00 weekly 0.7 https://trial.medpath.com/news/matica-biotechnology-partners-with-treovir-on-hsv-vectors-for-pediatric-brain-tumor-therapy 2024-12-05T01:35:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/matica-biotechnology-partners-with-treovir-on-hsv-vectors-for-pediatric-brain-tumor-therapy 2024-12-05T01:35:33+00:00 weekly 0.7 https://trial.medpath.com/news/pancreatic-cancer-patient-survival-doubled-with-high-dose-of-common-vitamin-study-finds 2024-12-05T00:51:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pancreatic-cancer-patient-survival-doubled-with-high-dose-of-common-vitamin-study-finds 2024-12-05T00:51:13+00:00 weekly 0.7 https://trial.medpath.com/news/suo-2024-real-world-treatment-and-clinical-outcomes-in-patients-with-mcrpc-treated 2024-12-05T00:29:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/suo-2024-real-world-treatment-and-clinical-outcomes-in-patients-with-mcrpc-treated 2024-12-05T00:29:28+00:00 weekly 0.7 https://trial.medpath.com/news/singapore-leads-asia-in-groundbreaking-gene-editing-trial-for-rare-heart-disease 2024-12-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/singapore-leads-asia-in-groundbreaking-gene-editing-trial-for-rare-heart-disease 2024-12-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/high-tumor-mutational-burden-linked-to-improved-survival-in-metastatic-colon-cancer 2024-12-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/high-tumor-mutational-burden-linked-to-improved-survival-in-metastatic-colon-cancer 2024-12-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/singapore-launches-25-million-clarion-program-to-transform-asian-lung-cancer-treatment 2024-12-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/singapore-launches-25-million-clarion-program-to-transform-asian-lung-cancer-treatment 2024-12-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lenvatinib-pembrolizumab-vs-chemotherapy-in-advanced-endometrial-cancer 2024-12-04T23:45:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lenvatinib-pembrolizumab-vs-chemotherapy-in-advanced-endometrial-cancer 2024-12-04T23:45:10+00:00 weekly 0.7 https://trial.medpath.com/news/can-fite-announces-8-year-survival-for-patient-in-phase-2-liver-cancer-study 2024-12-04T23:41:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/can-fite-announces-8-year-survival-for-patient-in-phase-2-liver-cancer-study 2024-12-04T23:41:05+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-rare-pediatric-disease-to-101-pgc-005-for-systemic-juvenile-idiopathic-arthritis 2024-12-04T23:37:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-rare-pediatric-disease-to-101-pgc-005-for-systemic-juvenile-idiopathic-arthritis 2024-12-04T23:37:29+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-revascor-r-rexlemestrocel-l-regenerative-globenewswire 2024-12-04T23:36:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-revascor-r-rexlemestrocel-l-regenerative-globenewswire 2024-12-04T23:36:34+00:00 weekly 0.7 https://trial.medpath.com/news/race-oncology-advances-rc220-phase-1-cancer-trial-tipranks-com 2024-12-04T22:57:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/race-oncology-advances-rc220-phase-1-cancer-trial-tipranks-com 2024-12-04T22:57:00+00:00 weekly 0.7 https://trial.medpath.com/news/editorial-hong-kong-drug-trials-institute-a-healthy-step-forward 2024-12-04T22:18:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/editorial-hong-kong-drug-trials-institute-a-healthy-step-forward 2024-12-04T22:18:12+00:00 weekly 0.7 https://trial.medpath.com/news/novel-heart-stent-for-kids-draws-praise-research-horizons 2024-12-04T22:17:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-heart-stent-for-kids-draws-praise-research-horizons 2024-12-04T22:17:30+00:00 weekly 0.7 https://trial.medpath.com/news/breaking-new-ground-in-immunology-inflammation-inside-precision-medicine 2024-12-04T22:17:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breaking-new-ground-in-immunology-inflammation-inside-precision-medicine 2024-12-04T22:17:21+00:00 weekly 0.7 https://trial.medpath.com/news/suo-2024-mevrometostat-pf-06821497-in-combination-with-enzalutamide-in-patients 2024-12-04T22:04:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/suo-2024-mevrometostat-pf-06821497-in-combination-with-enzalutamide-in-patients 2024-12-04T22:04:04+00:00 weekly 0.7 https://trial.medpath.com/news/biotech-startup-avoids-sec-penalties-through-voluntary-self-report-legal-dive 2024-12-04T22:03:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biotech-startup-avoids-sec-penalties-through-voluntary-self-report-legal-dive 2024-12-04T22:03:54+00:00 weekly 0.7 https://trial.medpath.com/news/corvus-pharma-s-cancer-drug-shows-breakthrough-immune-response-in-nature-journal-study 2024-12-04T21:14:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/corvus-pharma-s-cancer-drug-shows-breakthrough-immune-response-in-nature-journal-study 2024-12-04T21:14:24+00:00 weekly 0.7 https://trial.medpath.com/news/penn-state-college-of-medicine-beat-childhood-cancer-research-consortium-leading 2024-12-04T20:20:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/penn-state-college-of-medicine-beat-childhood-cancer-research-consortium-leading 2024-12-04T20:20:09+00:00 weekly 0.7 https://trial.medpath.com/news/eyepoint-doses-first-patient-in-second-global-phase-3-lucia-clinical-trial-of-duravyu-for-the 2024-12-04T20:09:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eyepoint-doses-first-patient-in-second-global-phase-3-lucia-clinical-trial-of-duravyu-for-the 2024-12-04T20:09:01+00:00 weekly 0.7 https://trial.medpath.com/news/fda-finalizes-pccp-guidance-for-ai-enabled-medical-devices-akin-gump 2024-12-04T19:13:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-finalizes-pccp-guidance-for-ai-enabled-medical-devices-akin-gump 2024-12-04T19:13:18+00:00 weekly 0.7 https://trial.medpath.com/news/ngs-and-novel-therapies-lends-to-prolonged-survival-outcomes-in-hr-her2-breast-cancer 2024-12-04T19:11:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ngs-and-novel-therapies-lends-to-prolonged-survival-outcomes-in-hr-her2-breast-cancer 2024-12-04T19:11:14+00:00 weekly 0.7 https://trial.medpath.com/news/what-to-know-about-metastatic-prostate-cancer 2024-12-04T19:02:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/what-to-know-about-metastatic-prostate-cancer 2024-12-04T19:02:27+00:00 weekly 0.7 https://trial.medpath.com/news/all-leukemia-clinical-studies-ongoing-recruitment-and-more-medicalnewstoday 2024-12-04T18:45:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/all-leukemia-clinical-studies-ongoing-recruitment-and-more-medicalnewstoday 2024-12-04T18:45:28+00:00 weekly 0.7 https://trial.medpath.com/news/phanes-therapeutics-pt217-granted-fast-track-designation-by-the-fda-for-nepc 2024-12-04T18:42:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phanes-therapeutics-pt217-granted-fast-track-designation-by-the-fda-for-nepc 2024-12-04T18:42:07+00:00 weekly 0.7 https://trial.medpath.com/news/impact-of-prior-dengue-infection-on-severity-and-outcomes-meta-analysis-of-placebo-controlled-trials 2024-12-04T18:42:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/impact-of-prior-dengue-infection-on-severity-and-outcomes-meta-analysis-of-placebo-controlled-trials 2024-12-04T18:42:06+00:00 weekly 0.7 https://trial.medpath.com/news/restem-receives-fda-orphan-drug-designation-for-its-ulsc-program-for-the-treatment-of 2024-12-04T18:39:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/restem-receives-fda-orphan-drug-designation-for-its-ulsc-program-for-the-treatment-of 2024-12-04T18:39:32+00:00 weekly 0.7 https://trial.medpath.com/news/sinai-health-s-innovative-clinical-trial-framework-leads-to-transformative-advances-in 2024-12-04T18:16:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sinai-health-s-innovative-clinical-trial-framework-leads-to-transformative-advances-in 2024-12-04T18:16:21+00:00 weekly 0.7 https://trial.medpath.com/news/ultrasound-controlled-crispr-offers-precision-in-treating-genetic-disorders-news-medical 2024-12-04T18:15:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ultrasound-controlled-crispr-offers-precision-in-treating-genetic-disorders-news-medical 2024-12-04T18:15:15+00:00 weekly 0.7 https://trial.medpath.com/news/initial-safety-findings-reported-on-luspatercept-plus-lenalidomide-for-non-del-5q-mds 2024-12-04T18:11:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/initial-safety-findings-reported-on-luspatercept-plus-lenalidomide-for-non-del-5q-mds 2024-12-04T18:11:58+00:00 weekly 0.7 https://trial.medpath.com/news/dewpoint-mitsubishi-partner-on-als-drug-in-deal-worth-up-to-480m-biopharma-dive 2024-12-04T18:11:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dewpoint-mitsubishi-partner-on-als-drug-in-deal-worth-up-to-480m-biopharma-dive 2024-12-04T18:11:11+00:00 weekly 0.7 https://trial.medpath.com/news/phase-ii-iii-pooled-data-analysis-imetelstat-benefit-in-mds-independent-of-prior-therapy 2024-12-04T17:51:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-ii-iii-pooled-data-analysis-imetelstat-benefit-in-mds-independent-of-prior-therapy 2024-12-04T17:51:09+00:00 weekly 0.7 https://trial.medpath.com/news/toripalimab-plus-chemotherapy-in-first-line-therapy-for-extensive-stage-small-cell-lung-cancer 2024-12-04T17:50:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/toripalimab-plus-chemotherapy-in-first-line-therapy-for-extensive-stage-small-cell-lung-cancer 2024-12-04T17:50:37+00:00 weekly 0.7 https://trial.medpath.com/news/md-anderson-research-highlights-ash-2024-special-edition 2024-12-04T17:39:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/md-anderson-research-highlights-ash-2024-special-edition 2024-12-04T17:39:35+00:00 weekly 0.7 https://trial.medpath.com/news/health-net-grant-for-uc-davis-stem-cell-program-to-improve-access-to-car-t-cell-therapy 2024-12-04T17:34:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/health-net-grant-for-uc-davis-stem-cell-program-to-improve-access-to-car-t-cell-therapy 2024-12-04T17:34:43+00:00 weekly 0.7 https://trial.medpath.com/news/review-highlights-gaps-in-publicly-funded-non-inferiority-clinical-trials-call-for-better 2024-12-04T17:17:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/review-highlights-gaps-in-publicly-funded-non-inferiority-clinical-trials-call-for-better 2024-12-04T17:17:22+00:00 weekly 0.7 https://trial.medpath.com/news/cidara-s-phase-ii-trial-testing-cd388-for-flu-prevention-fully-enrolled-with-5000-subjects 2024-12-04T16:51:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cidara-s-phase-ii-trial-testing-cd388-for-flu-prevention-fully-enrolled-with-5000-subjects 2024-12-04T16:51:57+00:00 weekly 0.7 https://trial.medpath.com/news/early-detection-and-interception-research-shows-promise-at-ash 2024-12-04T16:44:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/early-detection-and-interception-research-shows-promise-at-ash 2024-12-04T16:44:20+00:00 weekly 0.7 https://trial.medpath.com/news/antag-therapeutics-secures-eur80-million-in-weight-loss-therapy-financing-pharmatimes 2024-12-04T16:12:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/antag-therapeutics-secures-eur80-million-in-weight-loss-therapy-financing-pharmatimes 2024-12-04T16:12:38+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-data-and-patient-planning-can-keep-trials-from-collapsing-clinical-trials-arena 2024-12-04T16:11:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-data-and-patient-planning-can-keep-trials-from-collapsing-clinical-trials-arena 2024-12-04T16:11:38+00:00 weekly 0.7 https://trial.medpath.com/news/l-arginine-shows-potential-in-treating-spinocerebellar-ataxia-type-6-news-medical 2024-12-04T16:03:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/l-arginine-shows-potential-in-treating-spinocerebellar-ataxia-type-6-news-medical 2024-12-04T16:03:16+00:00 weekly 0.7 https://trial.medpath.com/news/stent-omission-after-ureteroscopy-and-lithotripsy-soul-in-the-michigan-urological-trials 2024-12-04T15:33:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stent-omission-after-ureteroscopy-and-lithotripsy-soul-in-the-michigan-urological-trials 2024-12-04T15:33:41+00:00 weekly 0.7 https://trial.medpath.com/news/texas-cardiac-arrhythmia-institute-at-st-david-s-medical-center-first-in-u-s-to-use-fda 2024-12-04T15:26:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/texas-cardiac-arrhythmia-institute-at-st-david-s-medical-center-first-in-u-s-to-use-fda 2024-12-04T15:26:59+00:00 weekly 0.7 https://trial.medpath.com/news/ocrelizumab-in-early-stage-relapsing-remitting-multiple-sclerosis-the-phase-iiib-pubmed 2024-12-04T14:53:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ocrelizumab-in-early-stage-relapsing-remitting-multiple-sclerosis-the-phase-iiib-pubmed 2024-12-04T14:53:16+00:00 weekly 0.7 https://trial.medpath.com/news/tribe-clinical-research-launches-new-drug-trial-focused-on-alzheimer-s-prevention 2024-12-04T14:47:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tribe-clinical-research-launches-new-drug-trial-focused-on-alzheimer-s-prevention 2024-12-04T14:47:12+00:00 weekly 0.7 https://trial.medpath.com/news/sonnet-biotherapeutics-unveils-breakthrough-cancer-drug-delivery-system-in-major-publication 2024-12-04T14:27:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sonnet-biotherapeutics-unveils-breakthrough-cancer-drug-delivery-system-in-major-publication 2024-12-04T14:27:04+00:00 weekly 0.7 https://trial.medpath.com/news/vivavision-to-advance-non-steroidal-therapy-in-phase-iii-following-phase-ii-win 2024-12-04T14:16:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vivavision-to-advance-non-steroidal-therapy-in-phase-iii-following-phase-ii-win 2024-12-04T14:16:00+00:00 weekly 0.7 https://trial.medpath.com/news/arrowhead-seeks-approval-to-begin-rnai-therapy-trial-for-obesity-treatment 2024-12-04T14:16:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arrowhead-seeks-approval-to-begin-rnai-therapy-trial-for-obesity-treatment 2024-12-04T14:16:00+00:00 weekly 0.7